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Tiivistelmä 
Ihmisalkion kantasolut (hES-solut) voivat tarjota ehtymättömän lähteen solusiirrännäi-
siin tulevaisuudessa. Nykyisissä viljelyolosuhteissa käytetään kuitenkin eläinperäisiä 
tuotteita, jotka aiheuttavat riskin eläinpatogeenien siirtymisestä ja solujen hylkimisestä 
ihmisen elimistössä. Lisäksi hES-solujen viljelyssä apuna tarvittavien tukisolujen työläs 
tuottaminen sekä kantasolujen hankala mekaaninen jakotapa tekevät hES-solujen suur-
ten määrien tuottamisesta vaikeaa. Tutkimuksen ensimmäisenä tavoitteena oli optimoi-
da hES-solujen viljelyolosuhteita kohti eläinvapaita olosuhteita testaamalla täysin 
eläinvapaita seeruminkorvikkeita (SR-3 ja X-Vivo 20) ja fibroblastien kasvutekijää 
(bFGF). Tutkimuksen muina tavoitteina oli löytää helpompi tapa hES-solujen jakami-
seen sekä testata biomateriaalien soveltuvuutta korvata tukisolut hES-solujen viljelmis-
sä.  
 Testauksen aikana hES-solujen erilaistumisaste pääteltiin ulkomuodon avulla ja 
vahvistettiin myöhemmin immunokemiallisesti käyttäen kantasoluspesifisiä markkereita 
erilaistumattomille soluille (AP, Oct-4 ja Nanog) ja erilaistuneille soluille (SSEA-1). 
Testatuilla SR-3 ja X-Vivo 20 menetelmillä kasvatetut hES-solut olivat täysin erilaistu-
neita, kun taas osa testi bFGF:n kanssa kasvatetuista soluista oli erilaistumattomia. 
Näiden solujen lukumäärä oli kuitenkin hyvin alhainen. Eläinvapaalla entsyymillä, 
Tryplellä, jaetut hES-solut olivat enimmäkseen erilaistumattomia ja niiden lukumäärä 
oli samankaltainen kontrollin kanssa. Lisäksi solujen karyotyyppi oli normaali 46,XX 
31 jakokerran jälkeen. Näistä hES-soluista erilaistetut soluaggregaatit, ns. embryoid 
bodit, ilmensivät eri alkion kerroksille yleisiä geenejä ja proteiineja käänteiskopioija-
PCR:n ja immunokemiallisten analyysien perusteella, osoittaen hES-solut pluripoten-
teiksi. Testatut biomateriaalit mahdollistivat hES-solujen kiinnittymisen kyllästetyssä 
kasvatusliuoksessa, mutta solujen erilaistumatonta kasvua ei pystytty osoittamaan. 
Solut, jotka siirrettiin takaisin tukisolujen päälle, olivat kuitenkin enimmäkseen erilais-
tuneita  
 Testatut SR-3, X-Vivo 20 ja bFGF sekä biomateriaalit eivät ylläpitäneet hES-
solujen erilaistumatonta kasvua paremmin kuin kontrolliolosuhteet, mutta testattu 
Tryple-jakotapa ylläpiti solujen kasvua hyvin. Vaikka tämä ei ollut nopeampi tapa kuin 
mekaaninen jako, se helpottaa ohuiden kantasolukolonioiden jakamista. Tryple-
jakotavalla koloniat voidaan paloitella pienempiin paloihin kuin mekaanisella jaolla, ja 
näin saadaan aikaan hES-solumäärän nopeampi monistuminen. 
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Abstract 
Human embryonic stem cells (hESCs) can offer an unlimited cell source for cellular 
transplantation, but the currently used culture conditions contain animal-derived prod-
ucts that bear a risk of transmitting animal pathogens and causing a rejection when cells 
are transplanted. In addition, the laborious production of feeders needed for hESC 
culture and the difficult mechanical passaging of hESCs make the large-scale produc-
tion of hESCs difficult. The first aim of this study was to optimize culture conditions for 
hESCs towards animal-free conditions by testing totally animal-free serum replace-
ments (SR-3 and X-Vivo 20) and basic fibroblast growth factor (bFGF). Other aims of 
the study were to find an easier way for hESC passaging and to test the possibility of 
growing hESCs without feeder cells using biomaterials.  
 The differentiation stage of the hESC colonies was determined during the testing 
by morphology and later confirmed with immunochemistry using markers specific for 
undifferentiated hESCs (AP, Oct-4 and Nanog) and for differentiated hESCs (SSEA-1). 
The hESCs grown with the SR-3 and X-Vivo 20 were all differentiated where as some 
of the hESCs grown with the test bFGF were undifferentiated. However, the amount of 
these cells was very low. The hESCs passaged with animal-free enzyme Tryple were 
mostly undifferentiated and the amount of these cells was similar with control. In addi-
tion, the cells had normal 46,XX karyotype after 31 passages. The embryoid bodies 
(EBs) differentiated from these hESCs expressed genes and proteins common to the 
three embryonic germ layers based on the reverse transcriptase-PCR and immunochem-
istry analysis, showing the pluripotency of the cells. The tested biomaterials allowed the 
attachment of hESCs in the presence of conditioned medium, but the undifferentiated 
growth of hESCs could not be determined. However, the cells plated back on feeders 
after one passage on biomaterials, were mostly differentiated. 
 The tested SR-3, X-Vivo 20 and bFGF as well as the biomaterials were not able to 
maintain the undifferentiated growth of hESCs better than the control conditions, but 
the Tryple passaging method supported the growth of hESCs well. Although it was not 
faster way than mechanical passaging, it makes the passaging of thin hESC colonies 
easier and the colonies could be split into smaller pieces than with mechanical passag-
ing, resulting in faster expanded growth of hESCs. 
Table of Contents 
Abbreviations ________________________________________________________ 6 
1. Introduction _______________________________________________________ 8 
2. Review of the literature _____________________________________________ 10 
2.1. Stem Cell ____________________________________________________________________10 
2.1.1. Embryonic stem cells _______________________________________________________11 
2.1.2. Adult stem cells ___________________________________________________________12 
2.2. Future possibilities of hESCs ____________________________________________________13 
2.3. Culture of hESCs _____________________________________________________________15 
2.3.1. Feeder cells ______________________________________________________________15 
2.3.2. Feeder-free culture of hESCs_________________________________________________17 
2.3.3. Human ESC culture medium _________________________________________________18 
2.3.4. Basic fibroblast growth factor ________________________________________________20 
2.3.5. Passaging of hESCs ________________________________________________________21 
2.3.6. Human ESC characterization ________________________________________________23 
2.4. Crucial issues and challenges ___________________________________________________24 
2.4.1. Animal-derived products ____________________________________________________24 
2.4.2. Good manufacturing practice ________________________________________________25 
2.4.3. Immune response __________________________________________________________25 
2.4.4. Somatic-cell nuclear transfer_________________________________________________26 
2.4.5. Ethical and legal issues _____________________________________________________27 
3. Aims of the research________________________________________________ 31 
4. Materials and Methods _____________________________________________ 32 
4.1. Feeder cells and cell culturing plastics ____________________________________________32 
4.2. Human embryonic stem cells ____________________________________________________32 
4.3. Human embryonic stem cell cultures______________________________________________33 
4.3.1. The culture method for the hESCs used as control cells ____________________________33 
4.3.2. The culture method for hESCs used in bFGF-testing ______________________________34 
4.3.3. The culture method for hESCs used in SR-3 -testing _______________________________34 
4.3.4. The culture method for hESCs used in X-Vivo 20 -testing___________________________34 
4.3.5. The culture method for hESCs used in Tryple-testing ______________________________35 
4.3.6. The culture method for hESCs used in biomaterial-testing __________________________36 
4.3.7. Statistics and calculations ___________________________________________________36 
4.4. Embryoid body formation_______________________________________________________37 
4.5. Immunochemistry _____________________________________________________________37 
4.5.1. Immunofluorescense analysis of hESCs_________________________________________37 
4.5.2. Immunoperoxidase staining of hESCs __________________________________________38 
4.5.3. Immunofluorescense analysis of the sections of EBs _______________________________38 
4.6. RNA extraction and reverse transcription __________________________________________39 
4.7. RT-PCR and agarose gel electrophoresis___________________________________________40 
4.8. Karyotyping __________________________________________________________________41 
5. Results ___________________________________________________________ 43 
5.1. The results of the test bFGF culture method for hESCs _______________________________43 
5.2. The results of the SR-3 culture method for hESCs ___________________________________46 
5.3. The results of the X-Vivo 20 culture method for hESCs _______________________________47 
5.4. The results of the Tryple culture method for hESCs __________________________________49 
5.5. The results of the biomaterial culture method for hESCs______________________________55 
6. Discussion ________________________________________________________ 57 
6.1. The test bFGF culture method for hESCs __________________________________________57 
6.2. The SR-3 and X-Vivo 20 culture methods for hESCs _________________________________59 
6.3. The Tryple culture method for hESCs _____________________________________________61 
6.4. The biomaterial culture method for hESCs _________________________________________64 
7. Conclusions _______________________________________________________ 66 
8. References ________________________________________________________ 67 
 
 6
Abbreviations 
 AFP  Alphafetoprotein 
 AFT  Adult fallobian tube 
 ANOVA Analysis of variance 
 AP  Alkaline phosphatase 
 ATCC  American type culture collection 
 α-sr-1  Alpha-sarcomeric actin 
 bFGF  Basic fibroblast growth factor 
 BMP  Bone morphogenetic protein 
 BSA  Bovine serum albumine 
 CM  Conditioned medium 
 DAPI  4´,6-Diamidino-2-phenylindole 
 EB  Embryoid body 
 ECM  Extra cellular matrix 
 EDTA  Ethylenediaminetetraacetic acid 
 FBS  Fetal bovine serum 
 FISH  Fluorescence in situ hybridization 
 hFF  Human foreskin fibroblast 
 FGFR  Fibroblast growth factor receptor 
 GADPH Glyseraldehyde 3-phosphate dehydrogenase 
 G-banding Giemsa-banding 
 GMP  Good manufacturing practice 
 hESC  Human embryonic stem cell 
 HIV  Human immunodeficiency virus 
 HLA  Human leukocyte antigen 
 hrbFGF Human recombinant basic fibroblast growth factor 
 HSA  Human serum albumin 
 hTERT Human telomerase reverse transcriptase 
 ICM  Inner cell mass   
 Ig  Immunoglobulin 
 IVF  In vitro fertilization 
 Ko-SR  Knock-out serum replacement 
 LIF  Leukemia inhibitory factor 
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 MEF  Mouse embryonic fibroblast 
 MHC  Major histocompatibility complex 
 mHC  Minor histocompatibility complex 
 MuLVs Murine leukemia viruses 
 ND-1  NeuroD-1 
 NF-68KD Neurofilament 68 kilodaltons 
 PB  Phosphate buffer 
 PBS  Phosphate buffered saline 
 PCR  Polymerase chain reaction 
 RT  Reverse transcriptase 
 SCID  Severe combined immunodeficient 
 SCNT  Somatic cell nuclear transfer 
 SR  Serum replacement 
 SSEA  Stage specific embryonic antigen 
 TGF  Transforming growth factor 
 TiO2  Titania 
 Ti  Titanium 
 TRA  Tumor related antigen  
 UM  Unconditioned medium 
 Zr  Zirkonium   
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1. Introduction 
Human embryonic stem cells (hESCs) have unique proliferation and differentiation 
capacities, which makes them a valuable source for cell transplantation and tissue 
engineering. Many have reported their ability to differentiate into a variety of specific 
cell types, including neurons, cardiomyocytes and insulin secreting cells (Lumelsky et 
al., 2001; Passier et al., 2005; Schulz et al., 2003). Human ESC-derived tissue-specific 
cells may have therapeutic potential for the treatment of Parkinson’s disease, spinal cord 
injury, heart disease, diabetes and other degenerative conditions.  
 Thomson et al. were the first to derive hESCs from the inner cell mass (ICM) of a 
blastocyst gained after in vitro fertilization (IVF) treatment and to culture them as 
permanent cell lines (Thomson et al., 1998). They used culture media containing fetal 
bovine serum (FBS) and mitotically inactivated mouse embryonic fibroblasts (MEFs) as 
feeder cells, which are believed to secrete factors into the medium and provide the 
necessary attachment for the undifferentiated growth of hESCs. However, animal-
derived components, nonhuman sera, and animal feeder cells in the cultures bear a risk 
of transmitting animal pathogens and animal proteins to hESCs (Amit et al., 2005; 
Martin et al., 2005). These components need to be removed from the culture in order to 
use the cells in transplantations for humans because they enhance the risk of immune 
rejection and zoonosis in cell transplantation recipients. 
 A feeder-free culture system has been developed using Matrigel or laminin coated 
surfaces with conditioned media collected from cultures of mouse feeder cells (Xu et 
al., 2001). This system eliminates the direct contact with MEFs, but it is still not ani-
mal-free. Numerous human feeders including human foreskin fibroblasts (hFFs) (Amit 
et al., 2003; Hovatta et al., 2003) and human adult marrow cells (Cheng et al., 2003) 
have been shown to support hESC growth, but the hESC culture media used in these 
studies contains animal-derived proteins. Human serum has been used instead of FBS in 
the hESC culture medium (Richards et al., 2002), but prolonged use of human serum 
leads to increased differentiation rates of hESCs (Koivisto et al., 2004; Richards et al., 
2003).  
 Amit et al. described serum-free culture conditions for hESCs using serum re-
placement (SR) in hESC culture medium and postnatal human fibroblasts as feeder 
cells, but the used cell lines were originally derived using FBS and MEFs (Amit et al., 
2003). The derivation of hESCs on hFFs and in SR has now been reported (Inzunza et 
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al., 2005). The addition of basic fibroblast growth factor (bFGF) in this culture system 
is required (Koivisto et al., 2004). Although this was a step forward, the SR and the 
bFGF used still contain animal-derived products. The SR form Gibco Invitrogen con-
tains bovine serum albumine (BSA) and bovine insulin. In addition the human recombi-
nant basic FGF (hrbFGF) from R & D Systems contains BSA as a preservative.  
 The passaging of hESCs is performed by enzymatic treatments (trypsin, dispase or 
collagenase IV) or by mechanical dissection. Mechanical dissection is laborious, de-
mands skills, and is time-consuming making the rapid expansion of hESCs hard if not 
impossible. The enzymes used for hESC passaging are often animal-derived and the use 
of enzymes can promote chromosomal aneuploidy, especially trisomy 12 and/or 17 
(Draper et al., 2004b; Mitalipova et al., 2005).  
 In the present study, the specific aim is to optimize culture conditions for hESCs 
towards animal-free conditions by testing an animal-free serum replacement that is 
added to the culture medium, an animal-free ready-made serum replacement medium 
and hrbFGF without BSA. Another aim of the study is to improve the passaging tech-
nique of hESCs using animal-free recombinant enzyme. The third aim is to test the 
possibility of growing hESCs without feeder cells using biomaterials.  
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2. Review of the literature 
2.1. Stem Cell 
Stem cell is a unique cell that can differentiate into many kind of cells found in the 
body. It can also proliferate as a stem cell, and in theory it can be cultured in vitro 
indefinitely (Figure 1). Stem cells can be found in embryo, fetus and some adult tissues. 
 
 
Figure 1. A stem cell. Each daughter cell can either remain a stem cell or differentiate 
into a specific cell usually through additional cell divisions. (Alberts et al., 2002). 
 
 Stem cells can also be categorized according to their differentiation potential. 
Totipotent cells have unlimited potential because they are capable of forming an entire 
organism. Fertilized oocyte is a totipotent cell and it creates identical totipotent cells 
with each cell division. By the fourth day, the totipotent cells begin to specialize, form-
ing a blastocyst. The outer layer of the cells (trophectoderm) in the blastocyst forms the 
placenta and other necessary tissues in the uterus required for the fetus to develop. The 
inner cell mass (ICM) of the blastocyst cannot form an entire organism anymore, but 
they can form virtually every type of tissues in the body and are therefore referred to as 
pluripotent cells. The pluripotent cells then further specialize into another type of stem 
cells, multipotent stem cells.  Multipotent stem cells are committed to give rise to cells 
that have a particular function, for example, blood stem cells give rise to red blood cells, 
white blood cells and platelets, and skin stem cells give rise to the different types of skin 
cells. These cells are considered committed stem cells or progenitor stem cells.  
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2.1.1. Embryonic stem cells 
The first human embryonic stem cell (hESC) line was derived in the Thomson labora-
tory at the University of Wisconsin (Thomson et al., 1998). Since then over a 250 new 
hESC lines have been derived in the world. Human ESCs are derived from preimplanta-
tion stage embryos, a process which involves culturing embryos to the blastocyst stage. 
Embryos are donated by infertile couples undergoing in vitro fertilization (IVF) treat-
ment. The quality of the embryos is determined according to their morphology and only 
good quality embryos are used in the infertility treatments. Excess or poor quality 
embryos that would otherwise be discarded are used in stem cell line derivation. The 
donated cleavage stage embryos (usually day 2 after fertilization) are cultured to the 
blastocyst stage. The zona pellucida surrounding the blastocyst is removed enzymati-
cally using pronase. Then the trophectoderm is removed by immunosurgery using rabbit 
antihuman whole serum and guinea pig complement serum (Hovatta et al., 2003).  The 
remaining ICM is then transferred onto specific cell layer, a feeder cell layer, and al-
lowed to proliferate. The undifferentiated cells, judged by morphology, are then chosen 
for each further cell splitting called passage. The derived cell line consists of embryonic 
stem cells that can proliferate and replace themselves indefinitely. 
 In natural conditions, in vivo, the ICM differentiates into generate primitive ecto-
derm, which ultimately differentiates into the three embryonic germ layers (endoderm, 
mesoderm and ectoderm) (Odorico et al., 2001). In vitro cultured hESCs have also the 
potential to differentiate into these germ layers. See Figure 2. 
 Human ESCs are pluripotent cells and their essential characteristics include (1) 
derivation from the preimplantation embryo, (2) prolonged undifferentiated prolifera-
tion, and (3) stable developmental potential to form derivatives of all three embryonic 
germ layers even after prolonged culture (Thomson et al., 1998). In addition, hESCs 
maintain a normal euploid karyotype over extended culture, express high levels of Oct4 
and Nanog, and show telomerase activity (Hoffman and Carpenter, 2005). Transcription 
factor Oct4 and its target gene Nanog are believed to take part in regulating the pluripo-
tency of hESCs (Chambers et al., 2003; Nichols et al., 1998) and the expression of 
telomerase is highly correlated with immortality in human cell lines (Kim et al., 1994). 
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Figure 2. Two fates of an in vitro fertilized zygote. The zygote is usually cultured 2-3 
days, after which it is transplanted into a uterus where it will develop into a human 
being. Alternatively the zygote can be cultured to blastocyst and the inner cell mass of 
the blastocyst can be isolated and cultured in vitro as stem cells. These cells can then be 
differentiated into cells representing all three embryonic germ layers. (Figure modified 
from Bradley et al. 2002).     
 
2.1.2. Adult stem cells 
When the embryo develops, the cells begin to differentiate and to lose their develop-
mental potential; nevertheless, pools of stem cells persist in several adult tissues. These 
multipotent cells have been found in various tissues, including bone marrow, peripheral 
blood, brain, liver and reproductive organs. These cells are maintained locally or by the 
systemic circulation and are activated by environmental stimuli for tissue regeneration 
(Asahara et al., 2000). 
 The differentiation potential of adult stem cells was previously though to be 
strictly limited to cell lineages found within the tissue of origin. However, today this 
view has been challenged. Several studies with mice have proposed that bone-marrow-
derived cells could give rise to muscle cells (Ferrari et al., 1998; Orlic et al., 2001). 
Furthermore, neural stem cells have proved to differentiate into many cell types includ-
ing hepatocytes, cardiomyocytes and epidermal cells (representing all three embryonic 
germ layers) (Clarke et al., 2000). In these studies the stem cells have been exposed to 
an environment that they typically would not encounter, which indicates that a stem cell 
may receive differentiation signals from neighboring cells. This might be the reason 
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why adult stem cells have previously seemed to generate only the types of cells present 
in a specific tissue (Clarke and Frisen, 2001). In a new environment, the stem cells 
could be able to respond to the signals, which would reprogram the stem cells to gener-
ate cells appropriate for the new environment (Frisen, 2002). This is known as stem cell 
plasticity. However, recent studies have suggested alternative explanations to stem cell 
plasticity. The experimental situations are often artificial and may be far from the 
physiological situation and often there has been damage to the tissue, which may be a 
perquisite for the observed effects (Frisen, 2002). Stem cell plasticity may also be the 
result of cell fusion, where adult somatic cells can gain differentiation potential by 
fusion with less differentiated cells (Terada et al., 2002; Ying et al., 2002). However the 
fact is none of the studies suggesting plasticity have excluded all alternative explana-
tions. 
2.2. Future possibilities of hESCs  
Human ESCs provide a lot of new information and hope for regenerative medicine. In 
addition, they offer a new model for understanding human development and therefore 
can help us to understand abnormal development. Experimental manipulation and 
functional studies of the post-implantation human embryo are ethically unacceptable. 
What is known about early human development so far is based on histological sections 
of a few human embryos and on analogy to experimental embryological studies of the 
mouse (Thomson and Odorico, 2000).  Because the earliest events of human develop-
ment are critically involved in human infertility, pregnancy loss and birth defects, 
hESCs could provide answers to these problems. 
 The hESCs can also be used to study the function of genes. In mouse, most gene 
function studies require the generation of transgenic or gene knockout animals. Human 
ESCs could provide in vitro approach that lacks the limitations of in vivo studies in 
mouse, for example the required long time, the relatively small-scale research and the 
need for animal testing. Human ESC lines that lack a specific gene or over express one 
can be created, and the influence of manipulation on the normal growth and develop-
ment of specific tissues can be studied (Keller and Snodgrass, 1999).  
 Human ESCs also provide valuable test system for evaluating the toxicity and 
efficacy of new medicines or chemicals. Currently used animal models provide us with 
important information about how the chemical acts in vivo, but they cannot always 
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predict the effects on human cells. Cultures of other human cells are also used for this 
purpose, but the cell lines have usually been cultured in vitro for long periods, which 
may have changed their characteristics compared to the in vivo cells. Human ESCs 
could be differentiated into specific cell types, which would mimic the in vivo response 
of the cells or tissue to the drug or toxin better than the long-term cell lines. The hESCs 
could be used in pharmaceutical, cosmeceutical and agrochemical industries instead of 
animal testing and they could offer safer, and potentially cheaper models for drug and 
chemical screening (Rolletschek et al., 2004; Seiler et al., 2004). 
 The most obvious application of hESCs is in cell-replacement therapies. At the 
moment, many diseases can be treated only by a transplant of tissue or organ, but in 
some cases the need for donated organs could be reduced or eliminated by using cell 
therapies. Cell transplantation could offer a treatment also for diseases that are currently 
untreatable, such as spinal cord injury. Studies with several animal models suggest that 
differentiated derivatives of ESCs could be used in cell transplantations (Paul et al., 
2002). Human ESCs have been differentiated into several different cell types, such as 
neurons, cardiomyocytes, oligodendrocytes, and insulin secreting cells, suggesting that 
hESCs could be used in the future as a treatment for Parkinsson’s disease, heart failure, 
spinal cord injury and diabetes, among others (Faulkner and Keirstead, 2005; Lumelsky 
et al., 2001; Nistor et al., 2005; Passier et al., 2005; Schulz et al., 2003)  
 Before any of these applications can be used properly, the differentiation of 
hESCs into specific cell types must occur efficiently in defined conditions. If undiffer-
entiated cells are transplanted the environmental signals will strongly influence on the 
differentiation of the cells. These signals are difficult or even impossible to predict and 
the transplant may form a teratoma. The hESCs can be directed to differentiation path-
ways in vitro by changing their culture conditions. Using End-2 cells and serum re-
placement (SR) Passier et al. were able to produce cardiomyocytes, and using MedII-
conditioned medium from Hepa2 cells Shulz et al. differentiated hESCs into neurons 
(Passier et al., 2005; Schulz et al., 2003). Insulin secreting structures have been able to 
form by supplementing basic fibroblast growth factor (bFGF) and nicotinamide into the 
growth medium and oligodendrocytes by using a combination of different hormones 
and growth factors (Lumelsky et al., 2001; Nistor et al., 2005). The effect of growth 
factors in the early differentiation of hESCs has been studied. Shuldiner et al. were able 
to alter the relative proportions of specific cell types with certain growth factors, but not 
to exclusively direct the differentiation into only one cell type (Schuldiner et al., 2000). 
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The effect of growth factors is highly dependable on the molecular signature of the cell, 
what kind of ligands and receptors the cell is producing. The molecular signature of 
undifferentiated hESCs and their differentiated derivatives have been compared and 918 
genes have been found to be enriched in the undifferentiated cells (Sato et al., 2003). 
These include ligand/receptor pairs and secreted inhibitors of the FGF, transforming 
growth factor-β/bone morphogenetic protein (TGFβ/BMP), and Wnt pathways. It is 
essential to the expanded culture of the hESCs to define the factors maintaining the 
pluripotency of the cells and it could also help to found the routes to the differentiation 
pathways. Skottman et al. compared the gene expression profiles of seven genetically 
independent hESC lines with those of nonlineage-differentiated cells derived from each 
line (Skottman et al., 2005). They found 8,464 transcripts expressed in all hESC lines, 
from which 280 genes were specific for hESCs and 219 genes were differentially ex-
pressed in all hESC lines compared with nonlineage-differentiated cells. The expression 
profiles of the seven hESC lines were similar, but there were some variation reflecting 
their genetic differences. This variation could influence on the preferential differentia-
tion potential of the hESC lines. However, from the 8,464 transcripts found, more than 
45 % have no yet-known biological function, indicating that a large number of factors 
influencing the hESC pluripotency are yet to be determined.   
2.3. Culture of hESCs 
2.3.1. Feeder cells 
The first hESC line was derived and cultured on mouse embryonic fibroblast (MEF) cell 
layer using 20 % fetal bovine serum (FBS) in the hESC culture medium (Thomson et 
al., 1998). The fibroblasts were gamma irradiated to obtain mitotically inactive cells 
that do not proliferate. These so-called feeder cells enable hESCs to remain undifferen-
tiated. The exact mechanism is not known, but the feeder cells are believed to secrete 
factors into the medium that conjugate with the extra cellular matrix (ECM) or interact 
with membrane bound proteins. They also provide attachment surface for hESCs that is 
essential for the undifferentiated growth of hESCs. Proliferative MEFs with certain 
densities are also able to support the growth of hESCs (Xie et al., 2005) but it seems 
unnecessary to use feeder cells that also themselves demand space to grow. These 
culture conditions, however, expose the hESCs to xenogeneic components. If the cells 
are ever to be used in cell replacement therapies, these xenogeneic components cause a 
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risk of infection by nonhuman pathogens and cell rejection by animal proteins on hESC 
surface. Mice harbor a variety of parasites, bacteria, and viruses potentially pathogenic 
for humans. Among these, endogenous retroviruses, including murine leukemia viruses 
(MuLVs) are able to infect human cells (Amit et al., 2005). Although Amit et al. did not 
found any evidence for infection of hESCs by MEF origin MuLV, it is a matter of great 
concern. Beside the feeder layer, also the medium used for the derivation and culture of 
feeder cells contains high quantities of animal-derived products, usually FBS. MEFs 
and animal-derived medium components contain the nonhuman sialic acid Neu5Gc 
which hESCs can incorporate (Martin et al., 2005). This could lead to an immune 
response mediated by natural antibodies to Neu5Gc present in most humans (Martin et 
al., 2005). The amount of Neu5Gc could be minimized by using human feeder cells and 
human serum or SR in the culture of hESCs.   
 Richards et al. demonstrated first that human feeders support the undifferentiated 
growth of hESCs (Richards et al., 2002). They used human adult fallobian tubal (AFT) 
epithelial feeder layer, human fetal skin and fetal muscle feeder layers successfully. The 
use of AFT feeder layer would be more convenient because the derivation of human 
fetal cell lines from human abortuses may cause ethical concerns. Although human 
feeders reduce the amount of animal pathogens, Richards et al. used FBS in the feeder 
culture medium as well as in hESC culture medium exposing the hESCs still to animal-
derived components. 
 Amit et al. managed to derive human foreskin fibroblast (hFF) feeders in human 
serum and in SR (Amit et al., 2003). They found no differences in their growth rates 
and morphologies compared to feeders grown in FBS. These feeder cells supported the 
undifferentiated growth of hESCs equally well as feeders derived in FBS. However, no 
other group has yet reported the derivation of feeder cells in SR, indicating that there 
might be some problems with the method. Amit et al. cultured hESCs on these feeder 
cells using culture medium containing 15 % SR instead of FBS. Although they managed 
to remove the main animal-derived components from the culture of hESCs, the used 
hESCs were still originally derived using FBS and MEFs.  
 Human FFs have been used also in the derivation of new hESC lines (Hovatta et 
al., 2003). These feeder cells were commercially available from American type culture 
collection (ATCC), which reduces the work amount greatly in hESC culture. The me-
dium used in the culture of both feeder cells and derived hESCs contained FBS, but the 
same group announced later the derivation of new hESC lines using the same commer-
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cially available feeders and hESC culture medium containing SR (Inzunza et al., 2005). 
The culture medium of the feeder cells were changed to medium containing SR shortly 
after their mitotic inactivation, but the derivation and growth of feeders still required 
FBS in the culture medium.  
 Various other human feeders have also been evaluated showing that adult skin and 
commercial fetal skin feeders maintain the undifferentiated growth of hESCs (Richards 
et al., 2003). Human marrow derived fibroblastic stromal cells have also the capacity to 
maintain the growth of undifferentiated hESCs in SR containing medium (Cheng et al., 
2003). However, not all human feeder cells support hESC growth equally well, for 
example human adult muscle cells (Richards et al., 2003).  
2.3.2. Feeder-free culture of hESCs 
In addition to different feeder cells, various coatings of culture plates have been tested 
for the culture of hESCs. One tested coating is commercially available Matrigel, which 
has a similar structure with the ECM. It is a soluble basement membrane extract of the 
Engelbreth-Holm-Swarm mouse tumor, and consists of laminin, collagen IV, entactin, 
heparan sulfate proteoglygan and various growth factors (Hoffman and Carpenter, 
2005). Although Matrigel might simplify the handling of hESC cultures, it is derived 
from mouse and cannot be used in clinical grade hESC cultures. Laminin, collagen IV, 
and fibronectin alone have also been tested for the hESC culture, where laminin showed 
to maintain the hESC growth equally well as Matrigel (Xu et al., 2001). Culture plates 
coated with human serum have also been reported to maintain the undifferentiated 
growth of hESC (Stojkovic et al., 2005). This coating has similar surface structure than 
Matrigel has, indicating that the three-dimensional structure may also be important.  
 An optimal alternative to feeders and coated matrixes would be the use of a bio-
material. Three-dimensional structures have already gained an interest in the field of 
stem cell differentiation. Networks made from different concentrations of collagen I 
fibers and fibronectin or laminin have been tested for mouse embryoid body (EB) 
differentiation from mouse ESCs (Battista et al., 2005). They concluded that both the 
composition and strength of the supportive matrix played an important role in EBs 
development. Also human EBs have been differentiated from hESCs on three-
dimensional scaffolds made out of poly(lactic-co-glycolic acid), poly(L-lactic acid) and 
porous alginate (Gerecht-Nir et al., 2004; Levenberg et al., 2003). The use of polymeric 
scaffolds in hESC differentiation holds a promise of engineering tissues and organs for 
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transplantation therapies. Biomaterials could be useful also to the undifferentiated 
growth of hESCs. With right kind of surface structure in combination with different 
growth factors, biomaterials could be used in steady quality large-scale culture of 
hESCs without feeder cells. Testing the biomaterials used in implants could be the first 
step. Titania coated titanium implants, for example, have good adherence to soft tissue 
(Areva et al., 2004). If this nonresorbable, reactive titania would be used to coat a 
culture dish, it could allow hESCs to attach to it. Considering that the attachment of the 
hESCs is crucial for their undifferentiated growth, this coating together with appropriate 
culture medium and growth factors could provide a promising culture condition for 
hESCs. 
2.3.3. Human ESC culture medium 
The animal-derived components must be removed also from the culture medium of 
hESCs. By now, almost all research groups have replaced the FBS from the hESC 
culture medium by SR. Amit et al. reported the use of SR first, and others have fol-
lowed (Amit et al., 2003). However, the most commonly used SR (from Gibco Invitro-
gen) contains animal-derived components, such as BSA, although in much less quanti-
ties than in FBS (Hoffman and Carpenter, 2005). Even a small amount of BSA in cul-
ture medium can cause the hESCs to incorporate Neu5Gc from the medium, which 
could cause an immune rejection if the cells were used in transplantation (Martin et al., 
2005). The amount of Neu5Gc could be minimized by using human serum or SR with 
only human orthologs or recombinant proteins. The use of human serum has been tested 
and the derivation of new hESC line in human serum containing medium and on human 
fetal feeders have been successful (Richards et al., 2002). However, the prolonged use 
of human serum in hESC culture medium leads to increased differentiation rates of 
hESCs (Koivisto et al., 2004; Richards et al., 2002; Richards et al., 2003).   
 Different conditioned media (CM) that are collected from feeder culture plates 
after 24 hours of incubation have been tested for the feeder-free culture of hESCs. Xu et 
al. reported first the use of Matrigel and MEF-CM in hESC culture (Xu et al., 2001). 
CM from human fetal and adult fibroblasts have also been tested together with Matrigel, 
human ECM, collagen I and laminin coatings, but these combinations did not support 
the undifferentiated growth of hESCs (Richards et al., 2002). The CM from one human 
source has been able to support the hESC growth cultured on Matrigel. Xu et al. derived 
fibroblast-like cells from hESCs and made them immortal by infecting the cells with a 
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retrovirus expressing human telomerase reverse transcriptase (hTERT) (Xu et al., 
2004). The CM from these cells supports the hESC growth under feeder-free conditions. 
The same CM was later used successfully with human serum matrix coating instead of 
Matrigel reducing the exposure of animal ingredients significantly (Stojkovic et al., 
2005). However, no other group has yet reported similar results.  
 The use of CM still requires the laborious culture of feeder cells. Few groups have 
been able to culture hESCs without feeder cells and even without CM. Human ESCs 
can be cultured on Matrigel with unconditioned medium (UM) if the cells are plated at 
high densities (Draper et al., 2004a). Draper et al. showed also that laminin with fi-
bronectin and/or collagen IV coatings supports the undifferentiated growth of hESCs in 
UM. However, the information about the serum used in the medium is not given. In 
addition, the culture of hESCs on feeder cells seems to support the hESC growth better 
than these coatings. Commercially available serum free medium (X-Vivo 10) that 
contains only human sourced recombinant proteins and growth factors also supports the 
growth of hESCs with Matrigel and human laminin coated surfaces (Li et al., 2005). 
However, the feeder-free culture conditions of hESCs are usually strongly dependable 
on high concentrations of exogenously added growth factors.  
 The various reported culture conditions are difficult to compare, because each 
group has used different base media, matrix or feeders, cell lines and cell passage num-
bers (one splitting equals one passage). Although hESCs have been shown to grow in 
each of these conditions, it is unclear which, if any, of the culture conditions is the 
optimal one. The use of single substrate for hESC growth is desirable, but the substrates 
used are still undefined components, and may have a lot-to-lot variability (Hoffman and 
Carpenter, 2005). It is also unclear whether the hESCs maintained in these different 
substrates are equivalent. In fact, the gene expression signature of hESCs is reported to 
be different when cultured with SR and FBS (Skottman et al., 2006). Skottman et al. 
found 1471 differentially expressed genes from which 470 genes were up-regulated in 
cells cultured in SR. These were genes that were mainly involved in signaling, devel-
opment, and cell proliferation, which could explain the increased growth rate of undif-
ferentiated cells in SR containing culture conditions compared to FBS (Koivisto et al., 
2004; Skottman et al., 2006). 
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2.3.4. Basic fibroblast growth factor 
Many growth factors have been implicated as regulators of hESC self-renewal, includ-
ing the members of transforming growth factor-β1/bone morphogenetic protein (TGF-
β1/BMP) superfamily, fibroblast growth factor (FGF) family and Wnt family. Combina-
tions of these growth factors or some of them alone have been reported to be important 
for maintaining the undifferentiated growth of hESCs. Amit et al. presented a feeder 
and serum free culture system based on fibronectin matrix and culture medium contain-
ing SR together with TGF-β1, basic FGF (bFGF) and with or without leukemia inhibi-
tory factor (LIF) (Amit et al., 2004). Although it was left uncertain how LIF influences 
the cells in this system it has been shown previously that LIF alone does not maintain 
the undifferentiated self-renewal of hESCs (Thomson et al., 1998). Basic FGF has also 
been used in combination with noggin, a BMP-antagonist. SR contains BMP-like activ-
ity, which can result to hESC differentiation (Xu et al., 2005). This activity can be 
reduced by noggin and bFGF or by high concentration of bFGF alone which allows the 
undifferentiated proliferation of hESCs in the absence of fibroblasts or CM (Xu et al., 
2005). It has been shown that the hESCs grown on feeder cells also required the addi-
tion of bFGF, but only in serum-free conditions (Amit et al., 2000; Koivisto et al., 
2004). The concentrations of bFGF used are usually between 4 to 10 ng/ml, but in 
feeder-free conditions the concentration used can be as high as 100 ng/ml.  
 Levenstein et al. have tested the effects of several different concentrations of 
bFGF using UM and Matrigel (Levenstein et al., 2006). 4, 24 and 40 ng/ml bFGF failed 
to support hESC culture, but 100 ng/ml and 250 ng/ml were capable of sustaining 
undifferentiated hESC proliferation with effectiveness comparable to CM. The need for 
high concentration of bFGF in UM may result from the faster degradation of bFGF in 
UM than in CM. Fibroblasts and fibroblast CM may sustain hESCs in part by secreting 
either protease inhibitors or binding proteins that modulate bFGF stability (Levenstein 
et al., 2006). 
 The ligand/receptor pairs of the FGF signaling pathway have shown to be en-
riched in the undifferentiated hESCs (Sato et al., 2003). These components of the path-
way suggests that endogenous as well as exogenous FGF signaling may play an essen-
tial role in the undifferentiated state. There are five isoforms of endogenously produced 
bFGF in humans. The low-molecular isoform (18 kDa) is released from the cell, bound 
to transmembrane receptors and believed to regulate cell proliferation and differentia-
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tion in autocrine or paracrine way. Human ESCs are found to secrete this isoform and 
can so activate the FGF receptors in an autocrine manner. Dvorak et al. suggests that all 
of these isoforms are similarly expressed in both undifferentiated and differentiated 
hESCs, but that the expression pattern of FGF receptors is changed. According to 
Dvorak et al. the four FGF receptor kinases, named FGFR1 through FGFR4, have the 
following expression order in undifferentiated hESCs: FGFR1 Æ FGFR3 Æ FGFR4 Æ 
FGFR2, with FGFR1 being most abundant. In differentiated cells, the expression pat-
tern is changed to FGFR1 Æ FGFR4 Æ FGFR3 Æ FGFR2 and the expression of all the 
receptors is dramatically elevated, suggesting that the relative levels of FGFR expres-
sion, rather than bFGF expression, is coupled to conditions that direct hESCs to differ-
entiate. (Dvorak et al., 2005) 
 Despite the common use of bFGF in hESC culture the function of bFGF is poorly 
defined. Kim et al. proposed that bFGF helps maintain self-renewal of hESCs through 
activation of the PI3K/Akt/PKB pathway (Kim et al., 2005). They revealed that if bFGF 
is removed from the media, the phosphorylation of the Akt/PKB molecule is decreased 
and the expressions of ECM molecules such as collagen type IV α1, laminin α1 and 
laminin receptor are nearly eliminated. These above studies highlight the important role 
of bFGF in the hESC culture. 
2.3.5. Passaging of hESCs 
The adherence of hESC to maintain their cell-cell interactions is important for their 
undifferentiated proliferation. The hESCs were originally passaged as small clumps, 
because of the previous reports of poor plating efficiency of single cell nonhuman 
primate ESCs (Thomson et al., 1995). The derivation of hESCs as cell clusters from 
ICM, however, results in heterogenous cell populations. Further passaging by clumps 
maintains the mixed cell populations, and it cannot be excluded that these populations 
consist of multiple precursors or committed stem cells that together differentiate to all 
embryonic germ layers instead of one cell. Homogenous hESC line should be created to 
proof the pluripotency of stem cells. The clonal derivation of hESCs from existing cell 
lines has been reported (Amit et al., 2000; Heins et al., 2006). The hESCs were dissoci-
ated into single cells by ethylenediaminetetraacetic acid (EDTA). The cells were then 
transferred to individual culture wells using micropipette under microscope. The re-
sulted cell lines were then tested to be stem cells and the pluripotency of the cells was 
shown. The cloning efficiency, however, was poor and only two groups have reported 
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the successful cloning of hESC lines, indicating that the methods must be further devel-
oped. 
 Whether the cell line is clonal or not, it must be passaged in clumps. There are 
two different ways to do this, mechanical or enzymatic. Mechanical passaging is per-
formed by splicing the colonies under a microscope, detaching the pieces from the plate 
and then transferring them onto fresh feeder plates. This method is time consuming and 
it demands skills, due to which it is difficult to process many cells at a time. Enzymatic 
method is faster and simpler. The cells are exposed to enzyme, which dissociates the 
cells. The dissociation is usually further improved by pipetting the cells gently. Typical 
reagents for this purpose include collagenase IV, trypsin and dispase. Some nonenzy-
matic solutions are also available, such as cell dissociation buffer. Some of these re-
agents are, however, xenogeneic proteins, for example trypsin is usually derived from 
porcine pancreas. These reagents are not recommended to use for hESCs. In contrast 
with enzymatic passaging were the clump size varies and the differentiated cells cannot 
be separated from the undifferentiated ones, with mechanical passaging the resulted cell 
clumps are uniform in size and it is easy to exclude the differentiated cells from the next 
passage. If the hESCs are needed in great amounts, might the enzymatic passaging be 
the best result because the enzymatic expansion produces larger amounts of hESCs in a 
short period of time (Oh et al., 2005). However the use of enzymes and cell dissociation 
buffer can promote chromosomal aneuploidy, especially trisomy 12 and/or 17, and 
quantitative differences for gene expression (Draper et al., 2004b; Mitalipova et al., 
2005). The karyotypic changes usually occur after extended passaging, so the enzymes 
may be used for shorter periods, about 15 passages, when manual dissection retains a 
stable karyotype even after 100 passages (Buzzard et al., 2004; Mitalipova et al., 2005). 
These two passaging techniques could be used in parallel, mechanical for maintenance 
of hESC lines and enzymatic for rapid expansion of cells for research or treatment 
purposes.    
 The ability of hESCs to maintain stable karyotype throughout extended culture 
periods is an important feature if the cells are ever to be used for transplantation, be-
cause karyotype changes in vivo are often associated with carcinogenesis. Not only 
enzymatic passaging, but other reasons as well can cause karyotypic changes, such as 
long-term cultivation (Inzunza et al., 2004). Human ESC lines are commonly tested 
with traditional karyotypic analyses that are low-resolution read-outs of the genome and 
can miss many alterations in the DNA that may affect cellular phenotype (Maitra et al., 
 23
2005). Maitra et al. found genomic alterations common to human cancers from late-
passage hESC lines, including aberrations in copy number, mitochondrial DNA se-
quence and gene promoter methylation. These genetic and epigenetic alterations show 
that continuous analysis of hESCs during culture is important. 
2.3.6. Human ESC characterization 
The hESCs are characterized first hand by their morphology. Human ESCs have a high 
ratio of nucleus to cytoplasm, prominent nucleoli and they form colonies with sharp 
borders (Thomson et al., 1998). A more precise characterization is done by different 
markers that are expressed in hESCs. Several cell-surface antigens are used to define 
undifferentiated hESCs, such as stage-specific embryonic antigens (SSEA-3 and SSEA-
4) and tumor-related antigens (TRA-1-60 and TRA-1-81), but SSEA-1 is expressed by 
some of the differentiated derivatives of hESCs, notably putative trophectoderm 
(Henderson et al., 2002; Thomson et al., 1998). The undifferentiated hESCs express 
also high levels of alkaline phosphatase (AP) and transcription factor Oct4 (Reubinoff 
et al., 2000). Oct4 has a target gene Nanog (Chambers et al., 2003), which is also used 
in hESC characterization. It is suggested that Nanog maintains the pluripotency of 
hESCs by preventing their differentiation to extra embryonic lineages (Hyslop et al., 
2005).  
 Human ESCs have a remarkable proliferation capacity, which might result from 
the high expression level of telomerase activity (Thomson et al., 1998). In fact, human 
telomerase reverse transcriptase has been used to create immortalized cell line from 
differentiated human cells (Xu et al., 2004). The telomerase activity can be used to 
characterize hESCs. 
 The important feature of hESCs is their ability to differentiate into all three em-
bryonic germ layers. The pluripotency of stem cells must be shown before the cells can 
be defined as stem cells. This is done by injecting the cells into severe combined immu-
nodeficient (SCID) mice allowing them to form teratomas, which include cells derived 
from all embryonic germ layers (Thomson et al., 1998). An option to animal testing is 
to allow hESCs to aggregate in suspension and form embryoid bodies (EBs). The EBs 
are grown without feeder cells in suspension with medium lacking bFGF. EBs are first 
composed of densely packed hESCs, but later the center becomes cavitated (Itskovitz-
Eldor et al., 2000). These structures usually contain differentiated cells and continued 
culturing can result in more differentiated cells. The EBs can be grown at least up to 
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100 days and the differentiation can be directed using growth factors (Khoo et al., 
2005). The different cell types can be recognized by isolating the RNA of the EBs and 
using PCR with primers selective for human genes or by embedding the EB on paraffin 
and immunoassaying the sections. Teratoma formation is still required to proof the 
pluripotency of new hESC lines, but EB culture should be regarded as a potential op-
tion. 
2.4. Crucial issues and challenges 
2.4.1. Animal-derived products 
The exposure of hESCs to animal components is a matter of serious concern. There is a 
risk of cell rejection and contamination with retroviruses and other pathogens that could 
be transmitted to the patient if these cells are used in therapeutic applications. The 
animal components should be eliminated from all the phases of hESC culture. The 
derivation of hESC line is the first phase that should be optimized. Currently used 
methods for zona pellucida and trophectoderm removal include the use of animal de-
rived products. Rodriguez et al. were the first to report the clinical-grade derivation of 
hESCs. They used acid Tyrore’s solution instead of pronase to zona pellucida removal 
and the cell lines were formed without immunosurgery, thereby eliminating exposure to 
animal antibodies and complement factors (Rodriquez et al., 2006). The next step is to 
grow the cells without feeders, or on human feeders that are cultured without animal 
derived components. The culture medium must also be totally animal free. Human 
serum or animal-free SR must be used instead of FBS. In addition, other components 
should be carefully checked and chosen animal-free. Some proteins might be human 
recombinant but could still contain BSA as a preservative, so it is very important to 
check the components carefully. The passaging of the cells should be done either me-
chanically or with enzymes or solutions that are not animal-derived. However, avoiding 
animal derived products is not enough to guarantee the safety of the patient. Human 
feeder cells and human serum can transmit human immunodeficiency virus (HIV)-1, 
HIV-2, Creutzfeldt-Jakob disease, hepatitis B or C viruses and other infectious agents to 
the recipient (Rodriquez et al., 2006). The screening of donor sources for these potential 
pathogens is required. 
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2.4.2. Good manufacturing practice  
Cells used for human transplantation are regulated by the European Union. According 
to new EU directives (2003/94/EC and 2004/24/EC), hESCs for transplantation must be 
cultured using conditions resembling good manufacturing practice (GMP). Following 
GMP regulations record keeping, qualified personnel, high sanitary standards, cleanli-
ness, equipment verification, validation of process and complaint management are 
required. The regulation enables the manufacturers to eliminate or minimize contamina-
tions and errors, and they protect the patient from non-effective or even dangerous 
treatment. In order to derive clinical-grade hESC lines, the used embryos and all con-
stituents of culture must be GMP-grade. 
2.4.3. Immune response 
Organ and tissue transplants between two unrelated individuals result often in graft 
rejection. This alloimmune response is usually controlled with immunosuppressive 
drugs, but it can result in numerous complications, including wound healing, infections, 
drug-related toxicities, skin malignancies, and low-grade lymphomas (Odorico et al., 
2001). Human ESC transplantation has the same immunological barriers as the conven-
tional transplantations have.  
 Allelic differences between graft and host at polymorphic loci, which give rise to 
histocompatibility antigens, cause the rejection. Human leukocyte antigen/major histo-
compatibility complex (HLA/MHC) antigens are usually the most dominant immu-
nological barriers to transplantation. The MHC class I molecules (HLA-A, HLA-B and 
HLA-C) and the MHC class II molecules (HLA-DR, HLA-DQ and HLA-DP) are most 
important (Bradley et al., 2002). The HLAs of the transplant and the recipient should be 
similar and the HLA matching between donor and recipient is usually done by compar-
ing three molecules, HLA-A, HLA-B and HLA-DR. Tissue allografts, which are HLA-
incompatible, will induce a CD4+ T-cell-dependent alloimmune response in recipients, 
which is more likely to result in acute graft rejection (Bradley et al., 2002). But even 
with patients who receive a perfect matched allograft, rejection can still occur and life-
long immunosuppressive therapy is needed. The MHC antigen levels in hESCs are 
sufficient for rejection by cytotoxic T cells, but the immunostimulatory capacity of the 
cells has been shown to be very low (Drukker et al., 2006), indicating that hESC based 
therapies could be a better option compared to conventional organ transplantations. 
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Although the immunostimulatory capacity of hESCs is low, HLA matching with the 
recipient would still be preferred.  
 The HLA matching between the hESCs and the recipient could be done by estab-
lishing stem cell banks with cell lines of many different HLA types. (Bradley et al., 
2002). In fact, the world’s first human stem cell bank has already been established in the 
United Kingdom (Healy et al., 2005). However, a large number of hESC lines needs to 
be screened before all possible haplotypes are obtained and this will take time and 
substantial funding. 
2.4.4. Somatic-cell nuclear transfer 
Perhaps the most promising method to overcome immune rejection of transplanted 
hESCs is somatic-cell nuclear transfer (SCNT), also known as genomic replacement 
and therapeutic cloning. With this technique the nucleus of an oocyte is removed and 
replaced by a nucleus extracted from a somatic cell of the patient. The cytoplasm of an 
oocyte has the ability to re-establish an embryonic gene expression program in the 
somatic cell nucleus, which could lead to a blastocyst development (Odorico et al., 
2001). This blastocyst could be used to derive a hESC line that would be custom-made 
for the patient (see Figure 3). Stem cells derived by SCNT should be an exact genetic 
match for the somatic cells of the donor, with the exception of mitochondrial genes, 
which are derived from the donor egg (Bradley et al., 2002).  
 SCNT has successfully been done with animals, for example with bovine cells. 
Cibelli et al. 1998 created ES-like cells with SCNT and transplanted them to bovine 
embryos, which resulted in calves with at least one transgenic tissue in them (Cibelli et 
al., 1998). The success with animals has raised the possibility of performing human 
SCNT for treatments of many diseases. In 2004 Hwang et al. reported the derivation of 
hESC line from cloned human embryo and later the creation of patient specific hESCs 
with SCNT, but these results have been revealed to be based on fabricated data (Hwang 
et al., 2005; Hwang et al., 2004). So far no group has reported a successful human 
SCNT. 
 There have already been discovered many problems with the SCNT. The poor 
availability of human oocytes and the low efficiency of the nuclear transfer procedure 
reported with animals are the first obstacles to overcome. Furthermore, if hESCs could 
be created the long population-doubling time of the cells would make the treatment 
slow (Odorico et al., 2001). In addition, SCNT would require the creation of a cell line 
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for every patient, unless the cell lines would be deposited in a stem cell bank waiting for 
the next patient with the same haplotype. 
 
Figure 3. Somatic-cell nuclear transfer (SCNT). The genetic material of an oocyte is 
removed and replaced by the genome of the patient’s somatic cell by a micropipette. 
The oocyte cytoplasm enables the somatic-cell genome to reprogram its genes and to 
start embryonic development. Embryo could be cultured to blastocyst stage and the 
inner cell mass could be isolated. Successful human SCNT has not yet been reported, so 
it is unclear whether this is possible with humans. (Figure from Bradley et al. 2002). 
  
2.4.5. Ethical and legal issues   
Although hESCs have a great therapeutic potential, they are also considered as a diffi-
cult ethical issue. Because the establishment of hESC lines involves the use of human 
embryos, it raises the question of ethical values at stake and the limits for such research. 
On the other hand, there is interest in new knowledge that can lead to treatment of 
incurable diseases. Opinions about the research are divided according to the different 
ethical, philosophical, and religious traditions. 
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 Those who view a preimplantation embryo as a person with rights often consider 
the intentional destruction equivalent to murder and that human rights are violated. But 
does a human embryo have rights as humans do? A widely recognized definition of a 
person is that one must have a nervous system capable of sentience and sometimes also 
of cognition and consciousness. The nervous system of a human embryo starts to de-
velop about 14 days after fertilization and the embryos used in the derivation of hESC 
lines are at the latest 8-day old (Stojkovic et al., 2004).  
 The view that embryo is not a person does not mean that it is regarded as an 
ordinary human tissue. Some people give embryos a special respect because of their 
ability to develop into a human being. The use of embryos is often judged by the pur-
pose. Creating an extended amount of embryos for IVF treatment to enable infertile 
couples to have children is widely accepted. The left over embryos from the treatment 
would be thrown away unless they were used in research. In this sense, the embryos are 
destroyed anyway. But the purpose of the research plays a major role in the acceptance 
of the hESC research. Many people accept it if the hESCs are used in developing treat-
ments for incurable diseases but if the goal is to use them for example in cosmetic 
testing it seems disrespectful to the embryo. But even if the goal is to save lives some 
people will not accept the destroying of an embryo because no life may be taken to 
preserve the life of another.  
 Therapeutic cloning raises even more resistance in people. The creation of an 
embryo by SCNT is hard to accept for some people, some might even say it is like 
playing God. The creation of an embryo for the sole purpose of destroying it and using 
one part of it could objectify the embryo and further objectify also woman.  
 Generating hESCs by SCNT is an asexual manner, where gametes do not combine 
through sexual fertilization. The embryo is created for research use and later maybe to 
therapeutic purposes. Therapeutic cloning tends to be misrepresented in the lay media 
and it is often connected to reproductive cloning. However, there are no intentions to 
culture the embryo beyond the blastocyst stage or implant that blastocyst in a uterus for 
reproduction. Some fear that when therapeutic cloning is accepted it is easy to move on 
to reproductive cloning, but the line between these two is very clear and therefore it is 
not necessary to prevent therapeutic cloning in order to prevent reproductive cloning. 
 Laws concerning the derivation of hESC lines vary greatly throughout the world 
(Table 1). In Finland the medical research act of 1999 covers the preconditions and use 
of human embryos up to 14 days of embryonic development. The derivation of hESC 
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lines is also allowed. The laboratories that carry out the research need a license from the 
National Authority for Medicolegal Affairs and an ethics committee must give suppor-
tive statement for research projects. Also the informed consent of both gamete donors is 
required. In the United States, there is no federal law regulating research on human 
embryos or the derivation of hESC lines. However, the President of the United States, 
George Bush, has announced his decision to allow Federal funds to be used for research 
on existing hESC lines that have been derived before the announcement (2001). There 
are no limitations with private funding but states can have their own laws, for example, 
the state of California has passed a law in 2002, allowing the procurement of hESCs 
from supernumerary embryos. (Matthiessen-Guyader, July 2004) 
 Other countries, such as Norway and Ireland, forbid any research on in vitro 
embryos, stem cells and cloning, whereas Luxemburg and Portugal have no specific 
legislation regarding human embryo research yet (Paul et al., 2002). Belgium, Sweden 
and United Kingdom have taken a step forward and accepted therapeutic cloning along 
with the derivation and research of hESCs (Matthiessen-Guyader, July 2004). Austria, 
Denmark, Finland, France, Germany, Greece, Ireland, Netherlands, Portugal and Spain 
have prohibited the creation of human embryos for research purposes in year 2003, but 
other countries have not yet a public position. Finland, however, has prohibited only the 
procurement of fertilized human embryo, which then excludes the SCNT from the law.  
 New regulations and a revision of the current legislation are under discussion in 
many countries. Stem cell research and therapeutic cloning have become a widely 
discussed topic in a short period of time and the legislations of several countries have 
not been able to keep up. All the ethical and medical aspects should be carefully consid-
ered and the resulting law should state clearly what is prohibited and what allowed. 
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Table 1. Stem cell policy worldwide (Matthiessen-Guyader, July 2004) 
Countries Regulations 
Italy Prohibition of the procurement of embryonic stem cells from human embryos 
Austria, Spain Prohibition of the procurement of embryonic stem cells from human embryos and 
the creation of human embryos for research purposes 
Ireland, Norway1 Prohibition of the procurement of embryonic stem cells from human embryos, the 
research on human embryonic stem cells and the creation of human embryos for 
research purposes. 
Germany Prohibition of the procurement of embryonic stem cells from human embryos but 
allowing for the importation of the human embryonic stem cell lines derived 
before the year 2002. Prohibition of the creation of human embryos for research 
purposes. 
Luxembourg, 
Portugal 
No specific legislation regarding human embryo research. Prohibition of the 
creation of human embryos for research purposes. 
Denmark, Finland, 
France, Greece, The 
Netherlands 
Allowing for the procurement of human embryonic stem cells from supernumer-
ary embryos. Prohibition of the creation of human embryos for research purposes. 
The United States1 Prohibition of the procurement of embryonic stem cells from human embryos 
with federal fund and the research with human embryonic stem cell lines created 
after 2001. 
Belgium, Sweden2, 
United Kingdom 
Allowing for the procurement of human embryonic stem cells from supernumer-
ary embryos and the creation of human embryos for stem cell procurement. 
1 (TENK et al., 2003) 
2 law (2005:39) in Sweden 
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3. Aims of the research 
There were three specific aims in this research. The first aim was to optimize culturing 
conditions for human embryonic stem cells (hESCs) towards animal-free conditions by 
testing a new totally animal-free basic fibroblast growth factor (bFGF), animal-free 
serum replacement that is added to the hESC culture medium and ready-made animal-
free serum replacement medium. The second aim was to find an easier way for cell 
passaging in order to replace mechanical splicing. Animal origin free Tryple Select was 
tested for this purpose. The third aim was to test the possibility of growing hESCs 
without feeder cells using three different biomaterials.  
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4. Materials and Methods 
4.1. Feeder cells and cell culturing plastics 
Commercially available human foreskin fibroblasts (hFFs) (CRL-2429, ATCC) were 
used as feeder cells for human embryonic stem cells (hESCs). The hFFs were taken 
from liquid nitrogen, thawed and cultured using medium containing 90 % IMDM w/L-
glut + Hepes (Gibco Invitrogen, USA), 10 % FBS (Gibco Invitrogen) and 50 U/ml 
Penicillin/Streptomycin (Cambrex, USA). The cells were cultured confluent and irradi-
ated at 35 Gy before being plated for hESCs. Next day the medium was changed to 90 
% IMDM w/L-glut + Hepes (Gibco Invitrogen), 10 % Knock-Out SR (Gibco Invitro-
gen) and 50 U/ml Penicillin/Streptomycin (Cambrex). The feeder plates were used up to 
two weeks. 
 Falcon 3003 tissue culture dishes and Falcon 3653 IVF cell culturing dishes (BD 
Biosciences, USA) were used for hFFs and hESC cultures. Also Falcon 4118 4-chamber 
cultureslides were used for culturing hESCs with biomaterials. 
4.2. Human embryonic stem cells 
With the permission of the ethics committee of the Karolinska Institute, the human 
embryonic stem cell (hESC) lines HS181, HS237 and HS293 have been derived from 
the inner cell mass (ICM) of blastocyst phase embryos, donated by couples undergoing 
in vitro fertilization (IVF) treatments in Karolinska Institute, Sweden. 
 The HS181 and HS237 cell lines have been originally derived and propagated 
using hFFs as feeder cells and using 20 % fetal bovine serum (FBS) in the hESC culture 
medium, but this was later changed to 20 % serum replacement (SR). HS293 cell line 
has not been in contact with FBS, it was derived using 20 % SR in the culture medium. 
HS181 and HS237 have karyotype 46,XX and HS293 has karyotype 46,XY. All the cell 
lines express stem cell markers specific for undifferentiated hESCs, alkaline phos-
phatase, Oct4, stage-specific embryonic antigen (SSEA)-4, tumor-related antigen 
(TRA)-1-60 and TRA-1-81 and form teratomas when injected into immunoincompetent 
mice. (Hovatta et al., 2003; Inzunza et al., 2005; Inzunza et al., 2004)  
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4.3. Human embryonic stem cell cultures 
The culture methods for hESCs used as control cells and for hESCs used in different 
testings are summarized in Table 2 and described more detailed below.  
 
Table 2. The summarized culture methods used for hESCs in this study. 
Tested 
method 
Cell line and passages or test 
times 
Medium Feeders Splitting 
method 
Controls HS181 (passages 49-79),  
HS237 (passages 60-65),  
HS293 (passages 41-59) 
 
hES-medium hFFs Mechanical 
bFGF HS181 (tested for 16 passages), 
HS237 (tested for 5 passages) 
hES-medium, where 
bFGF (R&D Systems) 
was replaced with 
bFGF from Chemicon  
 
hFFs Mechanical 
SR-3 HS181 (tested three times)  
HS237 (tested two times) 
 
hES-medium, where SR 
(Gibco Invitrogen) was 
replaced with SR-3 
(Sigma-Aldrich) 
 
hFFs Mechanical 
X-Vivo 20 HS181 (tested three times), 
HS237 (tested two times) 
 
X-Vivo 20 medium 
(Cambrex) 
hFFs Mechanical 
Tryple HS181 (tested for 31 passages) 
 
hES-medium hFFs Tryple method 
Biomaterials HS293 (tested five times) UM hES-medium or 
CM hES-medium from 
hFFs 
No 
feeders 
 
No splitting 
Abbreviations: hFFs, human foreskin fibroblasts; bFGF, basic fibroblast growth factor; 
SR, serum replacement; UM, unconditioned medium; CM, conditioned medium 
 
4.3.1. The culture method for the hESCs used as control cells 
The hESCs used as controls for the different testings were cultured using hFFs as feeder 
cells in hES-medium, containing 80 % Ko-DMEM (Gibco Invitrogen), 20 % Ko-SR 
(Gibco Invitrogen), 2mM GlutaMax (Gibco Invitrogen), 1 % Non-essential amino acids 
(Cambrex), 50 U/ml penicillin/streptomycin (Cambrex), 0,1 mM 2-mercaptoethanol 
(Gibco Invitrogen) and 8 ng/ml human recombinant basic fibroblast growth factor 
(hrbFGF, R & D Systems, USA). The medium was changed daily.  
 After 5-9 days of growing, the undifferentiated cell colonies (judged by morphol-
ogy of the cells) were passaged mechanically into small pieces using a scalpel and a 
needle. The pieces were then transferred with a pipette onto fresh feeder plates.  
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 The hESC lines used for testings were HS181 at passages between 49-79, HS237 
at passages between 60-65 and HS293 at passages between 41-59 (one splitting equals 
one cell passage). 
4.3.2. The culture method for hESCs used in bFGF-testing 
The hrbFGF from R & D Systems used in the culture of control hESCs contains BSA 
and the carrier-free hrbFGF, from Chemicon, International, was tested to replace it. The 
culture method for hESCs in bFGF-testing was similar with the method used for control 
hESCs, except for the medium used that was the test bFGF medium, containing 80 % 
Ko-DMEM (Gibco Invitrogen), 20 % Ko-SR (Gibco Invitrogen), 2mM GlutaMax 
(Gibco Invitrogen), 1 % Non-essential amino acids (Cambrex), 50 U/ml penicil-
lin/streptomycin (Cambrex), 0,1 mM 2-mercaptoethanol (Gibco Invitrogen) and 8 ng/ml 
or 20 ng/ml or 40 ng/ml hrbFGF (Chemicon). The hESCs from HS181 were grown in 
the test bFGF medium for 16 passages and HS237 for 5 passages.  
4.3.3. The culture method for hESCs used in SR-3 -testing 
The Ko-SR from Gibco Invitrogen used in the culture of control hESCs contains bovine 
serum albumine (BSA) and bovine insulin. Animal-free SR, SR-3 (Sigma-Aldrich, 
Germany), was tested to replace it. The hESCs used for SR-3 -testing were adapted to 
the SR-3 by passaging the cells onto a fresh feeder plate and using hES-medium where 
the amount of SR consisted the control SR (Ko-SR) and the tested SR-3 first with the 
ratio of 4:1. When the cells were passaged the ration was changed to 1:1, in the next 
passage the ratio was changed to 1:4 and finally the control SR was totally replaced by 
SR-3. The SR-3 was tested as 10 % and 20 % in hES-medium, where the Ko-SR was 
removed. The hESCs in SR-3 -testing were passaged in the same way as the control 
cells and the medium was changed daily. The SR-3 -testing was repeated three times 
with hESCs from HS181 cell line and two times with HS237 cell line. 
4.3.4. The culture method for hESCs used in X-Vivo 20 -testing  
Animal free SR medium, X-Vivo 20 (Cambrex), was also tested to replace the currently 
used animal components containing Ko-SR. The hESCs used for X-Vivo 20 -testing 
were adapted to the X-Vivo 20 by passaging the cells onto a fresh feeder plate and using 
hES-medium and X-Vivo 20 medium together first with the ratio of 4:1. When the cells 
were passaged the ration was changed to 1:1, in the next passage the ratio was changed 
to 1:4 and finally the hES-medium was totally replaced by the X-Vivo 20 -medium. The 
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X-Vivo 20 –medium was supplemented with 2mM GlutaMax (Gibco Invitrogen), 1 % 
Non-essential amino acids (Cambrex), 0,1 mM 2-mercatoethanol (Gibco Invitrogen) 
and 8 ng/ml hrbFGF (R&D Systems). The hESCs used in X-Vivo 20 -testing were 
passaged in the same way as the control cells and the medium was changed daily. The 
X-Vivo 20 -testing was repeated three times with hESCs from HS181 cell line and two 
times with HS237 cell line.   
4.3.5. The culture method for hESCs used in Tryple-testing 
The mechanical passaging is laborious and difficult and a new enzymatic passaging 
method was tested to replace it. The hESCs used for Tryple-testing were cultured in the 
same way as the control cells, except for the passaging method used. After 4-7 days of 
culture, cells were passaged using Tryple Select (Gibco Invitrogen), which is an animal-
free recombinant enzyme produced with microbial fermentation. The undifferentiated 
colonies (judged by morphology) were lined from feeder cells by scalpel, then the hES-
medium was removed and pre-warmed (+37 °C) Tryple was added to the plate (Figure 
4). The cells were incubated for 1 minute and the feeder cells along with the differenti-
ated cells were removed as a one carpet from the plate by drawing with a scalpel. The 
lined undifferentiated stem cell colonies stayed intact. The Tryple and the detached cells 
were removed from the plate with a pipette and hES-medium was added again. Then the 
hESC colonies could be easily spliced to smaller pieces by scalpel and removed from 
the bottom of the plate by scraping. The pieces were transferred to fresh feeder plates. 
The hESCs used for Tryple-testing were from HS181 cell line and the cells have been 
passaged with Tryple now for 37 times.  
 
 
Figure 4. The Tryple passaging method for hESCs. (A) The undifferentiated areas of 
hESC colonies were lined from the feeder cells and from the differentiated cells with a 
scalpel. (B) The hES-medium was removed and prewarmed Tryple was added to the 
plate. After 1 minute incubation the feeder layer and the differentiated cells were re-
moved along with the Tryple and hES-medium was added again. (C) The undifferenti-
ated areas of hESC colonies were spliced into smaller pieces by a scalpel and detached 
by scraping with a needle. The pieces were then transferred to fresh feeder plates.   
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 Different splitting techniques were tested and the method above was chosen for 
the actual testing. Other techniques were (1) removing the feeders around the colonies 
without scalpel separation, (2) collecting all the cells in one clump and pipetting it into 
smaller pieces or (3) scalpelling it into smaller pieces. 
4.3.6. The culture method for hESCs used in biomaterial-testing 
Three different biomaterials were tested for feeder-free culture of hESCs in order to get 
rid of the laborious production of feeder cells. Titania (TiO2), titanium (Ti) and zirco-
nium (Zr) coated glass pieces (10 mm x 10 mm) from Vivoxid Ltd. were placed in the 
chambers of a 4-chamber cultureslide. On chamber without a biomaterial was used as a 
control. Two different media were tested for the feeder-free culture of hESC on bioma-
terials, normal unconditioned hES-medium and conditioned hES-medium that was 
collected from hFF feeder plates after 24 h of incubation. The hESCs were passaged 
mechanically and the pieces were placed into the biomaterial chambers and into the 
chamber used as a control. The media were changed daily. The biomaterial-testing for 
the feeder-free culture of hESCs from HS293 cell line was repeated five times for every 
biomaterial.  
 The hESCs grown on the biomaterials were tried to passage by scraping with a 
needle, but the cells detached as single cells and did not attach to the biomaterials 
anymore. The hESC colonies grown on the biomaterials were detached gently by a tip 
of a pipette in as big pieces as possible and transferred back on feeder cells. The cell 
pieces attached to the feeder cells and were allowed to proliferate.   
4.3.7. Statistics and calculations 
The numbers of undifferentiated, partly differentiated and differentiated hESC colonies 
were counted before every passage in all culture conditions and the percentage values 
were calculated, in order to see how the test conditions maintain and support the ex-
panded growth of hESCs. The better the condition maintain the undifferentiated growth 
of hESCs, the more new plates can be obtained from one culture plate after passaging, 
expanding the growth of hESCs.  
 The areas of the undifferentiated hESC colonies were measured daily, using the 
EclipseNet computer program (Nikon, USA). The areas of the colonies could be meas-
ured only from the hESC colonies grown with control, test bFGF and Tryple culture 
methods, because there were no undifferentiated colonies in SR-3 and X-Vivo 20 
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testings after the adaptation of the cells and the hESCs grown on the biomaterials had 
entirely different morphology than the control cells, making the determination of the 
undifferentiated cells impossible. The measured areas were used to calculate the instant 
growth rates (G values) of the colonies. The G-values were calculated using the follow-
ing formula: G=ln[(A2/A1)/∆t], where A1 is the area of the colony at time point 1, A2 is 
the area of the colony at time point 2 and ∆t is the change of time. The data is expressed 
as mean ± SD. The differences between groups was analyzed using one-way ANOVA 
and the differences were considered statistically significant at p < 0,05. 
4.4. Embryoid body formation 
The pluripotency of the hESCs cultered with Tryple-method was showed by culturing 
embryoid bodies (EBs). The EBs were formed by mechanically dissecting undifferenti-
ated hESC colonies and transferring the resulted pieces onto a culture dish without 
feeder cells. The EBs were cultured in hES-medium without bFGF approximately for 30 
days before the isolation of RNA and approximately for 70 days before immunoassay-
ing. The medium was changed every 2-3 days.  
4.5. Immunochemistry 
4.5.1. Immunofluorescense analysis of hESCs 
The hESCs grown with the bFGF, SR-3, X-Vivo 20 and Tryple culture method were 
determined undifferentiated or differentiated by immunocytochemistry. Also the hESC 
colonies grown on feeder cells after one passage on the biomaterials were analyzed in 
the same way. The primary antibodies used against markers expressed in undifferenti-
ated hESCs were goat anti-Nanog and goat anti-Oct4, both at 1:100 dilutions. Primary 
antibody used against differentiated hESC marker was mouse anti-SSEA-1 (1:100). All 
the primary antibodies were from Human Embryonic Stem Cell Marker Antibody Panel 
(SC008, R&D Systems). Secondary antibodies used were Alexa Fluor 488 donkey anti-
goat IgG (1:600) (Molecular Probes Invitrogen, USA) for anti-Nanog and anti-Oct4 and 
Rhodamine Red conjugated donkey anti-mouse IgM (1:800) (Jackson Immunoresearch 
Laboratories, USA) for anti-SSEA-1. All experiments included negative controls for 
staining where fibroblasts or only the secondary antibody were used.  
 The hESCs were fixed with 4 % paraformaldehyde for 20 minutes at room tem-
perature and washed 3 times for 5 minutes in phosphate buffered saline (PBS, Cam-
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brex). The immunostaining was performed according to the following protocol: (1) the 
cells were permeabilized and the non-specific binding of the antibody was blocked with 
treatment in 0.1 % Triton X-100 (Sigma-Aldrich), 1 % BSA (Sigma-Aldrich), 10 % 
normal donkey serum (Sigma-Aldrich) in PBS at room temperature for 45 minutes; (2) 
the cells were incubated with primary antibodies diluted in 1 % BSA, 1 % normal 
donkey serum in PBS overnight at +4 °C. For negative control only the dilution solution 
was used. The cells were then washed 3 times for 5 minutes in PBS containing 1 % 
BSA; (3) the cells were incubated with secondary antibodies diluted in PBS containing 
1 % BSA for 60 minutes at room temperature in the dark. The cells were then washed 2 
times for 5 minutes in PBS and 2 times for 5 minutes in phosphate buffer (PB).  
 Finally, the cells were mounted in Vectashield with DAPI (Vector Laboratories, 
USA) and covered with a cover-slip. The cells were examined with a Nikon Eclipse 
TE2000-S microscope and photographed with a Nikon Coolpix 5400 camera. 
4.5.2. Immunoperoxidase staining of hESCs 
 Undifferentiated hESCs express high levels of Alkaline Phosphatase (AP). The undif-
ferentiated state of hESCs grown with the Tryple and with the bFGF culture method 
was analyzed using the Alkaline Phosphatase Detection Kit (Chemicon). 
 The hESCs were fixed with 4 % paraformaldehyde for 2 minutes at room tem-
perature and washed 3 times for 5 minutes in phosphate buffered saline (PBS, Cam-
brex). The AP staining was performed according to the following protocol: (1) Fast Red 
Violet (FRV, supplied with the kit), Naphthol AS-BI phosphate solution (supplied with 
the kit) and water were mixed in a 2:1:1 ratio. The hESCs were incubated in the stain 
solution for 15 minutes at room temperature in the dark; (2) the cells were then washed 
3 times for 5 minutes in PBS and examined with a Nikon Eclipse TE2000-S microscope 
and photographed with a Nikon Coolpix 5400 camera. The hESCs expressing AP were 
stained red and the differentiated hESCs were colorless.  
4.5.3. Immunofluorescense analysis of the sections of EBs 
The pluripotency of the hESCs grown with the Tryple culture method was shown by 
analyzing the sections of EBs by immunohistochemistry. The EBs were embedded in 
paraffin and 3 µm sections were cut and placed on microscope slides by Histola Ltd. 
The primary antibodies used against ectodermal markers were goat anti-Sox-1 (1:20, 
Santa Cruz) and mouse anti-nestin (1:100, Chemicon), against endodermal marker was 
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goat anti-alphafetoprotein (AFP 1:20, Santa Cruz, USA), and against mesodermal 
marker was mouse anti α-sarcomeric actin (α-sr-1, 1:100, Sigma-Aldrich). Secondary 
antibodies (all from Jackson Immunoresearch Laboratories) used were Rhodamine Red 
conjugated donkey anti-goat IgG for anti-Sox-1 and anti-AFP, Rhodamine Red conju-
gated donkey anti-mouse IgG for anti-Nestin and Rhodamine Red conjugated donkey 
anti-mouse IgM for anti α-sarcomeric actin. All experiments included negative controls 
for staining where fibroblasts or only the secondary antibody were used. 
 The EB samples on the microscope slides were deparafinized by incubating them 
in the following solutions: 2 times for 5 minutes in xylene (Sigma-Aldrich), 2 times for 
5 minutes in absolute ethanol, for 5 minutes in 95 % ethanol, for 3 minutes in 90 % 
ethanol, for 3 minutes in 85 % ethanol and 3 times for 1 minute in distilled water. The 
EB samples on the slides were then treated with antigen retrieval citrate buffer for 20 
minutes at +95 °C, followed by 20 minute cooling at room temperature. The EB sam-
ples on the slides were washed 2 times for 2 minutes in distilled water. 
 The immunostaining was performed according the protocol described in section 
4.7.1 and finally, the EB samples were mounted in Vectashield with DAPI (Vector 
Laboratories) and covered with a cover-slip. The EB samples were examined with a 
Nikon Eclipse TE2000-S microscope and photographed with a Nikon Coolpix 5400 
camera. 
4.6. RNA extraction and reverse transcription 
Total RNA was isolated from EBs differentiated from the hESCs grown with the Tryple 
culture method by using RNeasy micro kit (Qiaken, Germany). The RNA extraction 
was performed according to the following protocol: (1) 350 µl of Buffer RLT (supplied 
with the kit) with added β-Mercaptoethanol (Sigma-Aldrich) was added per two or three 
embryoid bodies, and the sample was homogenized by vortexing; (2) 350 µl of 70 % 
ethanol was added, and the suspension was mixed by pipetting. The sample was applied 
to an RNeasy MinElute Spin Column in a 2 ml collection tube (supplied with the kit) 
and centrifuged for 15 s at 10,000 rpm. The flow-through was discarded; (3) 350 µl 
Buffer RW1 was added to the column and centrifuged for 15 s at 10,000 rpm to wash 
the column. The flow-through was discarded; (4) 10 µl of DNase I stock solution (sup-
plied with the kit) was added to 70 µl of Buffer RDD (supplied with the kit) and mixed 
by inverting the tube. The DNase I incubation mix (80 µl) was pipetted onto the silica-
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gel membrane of the column and incubated for 15 minutes at room temperature; (5) 350 
µl of Buffer RW1 was added to the column and centrifuged for 15 s at 10,000 rpm. The 
flow-through and the collection tube were discarded; (6) the column was transferred 
into a new collection tube, 500 µl of Buffer RPE (supplied with the kit) was added to 
the column and centrifuged for 15 s at 10,000 rpm to wash the column. The flow-
through was discarded; (7) 500 µl of 80 % ethanol was added to the column and centri-
fuged for 2 minutes at 10,000 rpm to dry the silica-gel membrane. The flow-through 
and the collection tube were discarded; (8) The column was transferred into a new 2 ml 
collection tube. The cap of the spin column was opened and centrifuged for 5 minutes at 
15,000 rpm. The flow-through and the collection tube were discarded; (9) for eluation, 
the column was transferred to a new 1,5 ml collection tube. 14 µl of RNase-free water 
was pipetted onto the center of the silica-gel membrane and centrifuged for 1 minute at 
15,000 rpm. The concentration and quality of isolated RNA was studied by measuring 
absorbance at 260 and 280 nm with a ND-1000 Spectrophotometer (NanoDrop Tech-
nologies, USA).   
 Complementary DNA (cDNA) was synthesized from 50 ng of total RNA using 
Sensiscript Reverse Transcription Kit (Qiaken). 2 µl of Oligo-dT primer (10 µM, Fer-
mentas, USA) and 1 µl RNase inhibitor (40 units/µl, Fermentas) diluted in 1x Buffer RT 
for a concentration of 10 units/µl were mixed with 50 ng of template RNA. 2 µl of 10x 
Buffer RT, 2 µl of dNTP Mix (5 mM each dNTP) and 1 µl of Sensiscirpt Reverse 
Transcriptase (all supplied with the kit) were added to the reaction mixture. RNase-free 
water was added so that the final volume of the mixture was 20 µl. The reaction mixture 
was incubated for 60 minutes at +37 °C.  
4.7. RT-PCR and agarose gel electrophoresis 
In addition to the immunochemistry analysis of EB sections, the pluripotency of the 
hESCs grown with the Tryple culture method was shown also by performing reverse 
transcription-PCR (RT-PCR) using cDNA, made from the extracted RNA of the EBs, as 
a template. Primers, summarized in Table 3, were used to detect the expression of 
markers characteristic of ectoderm (neuroD-1, neurofilament 68KD), endoderm (α-
fetoprotein) and mesoderm (α-cardiac actin). Glyseraldehyde 3-phosphate dehydro-
genase (GAPDH) was used as a housekeeping control.  
 41
 Approximately 500 ng of cDNA was used as template in the PCR reactions. 
Negative control contained sterilized water instead of cDNA template. All the reagents 
used were from Fermentas. The PCR reaction was as follows: 17.15 µl sterilized water, 
2.5 µl 10x Taq buffer with KCl, 0.2 µl 25 mM dNTP mix, 1 µl of 5 µM primer-F, 1 µl 
of 5 µM primer-R, 2 µl 25 mM MgCl2, 0.15 µl Taq DNA Polymerase and 1 µl cDNA. 
The PCR reactions were carried out in the Eppendorf Mastercycler as follows: denatura-
tion at 95 °C for 3 minutes and 40 cycles of denaturation at 95 °C for 30 s, annealing at 
55 °C for 30 s and extension at 72 °C for 1 minute, followed by final extension at 72 °C 
for 5 minutes. 
 The PCR products were analyzed by electrophoresis on 1.5 % agarose gel con-
taining 0.1 µg/ml ethidium bromide (Sigma-Aldrich) and DNA standard (MassRulerTM 
DNA Ladder Mix, Fermentas).  
 
Table 3. PCR primers (Proligo, USA) used to detect gene expression in EBs. 
 
Gene product 
 
Forward (F) and reverse (R) primers (5’-3’) 
 
Product size (bp) 
ND-1 F: AAGCCATGAACGCAGAGGAGGACT 
R: AGCTGTCCATGGTACCGTAA 
579 
NF-68KD F: GAGTGAAATGGCACGATACCTA 
R: TTTCCTCTCCTTCTTCACCTTC 
473 
AFP F: GCTGGATTGTCTGCAGGATGGGGAA 
R: TCCCCTGAAGAAAATTGGTTAAAAT 
216 
α-cardiac actin F: GGAGTTATGGTGGGTATGGGTC 
R: AGTGGTGACAAAGGAGTAGCCA 
486 
GAPDH F: AGCCACATCGCTCAGACACC 
R: GTACTCAGCGGCCAGCATCG 
302 
Abbreviations: ND-1, neuroD-1; NF-68KD, neurofilament 68 KD; AFP, α-fetoprotein; 
GAPDH, glyseraldehyde 3-phosphate dehydrogenase; bp, base pairs  
4.8. Karyotyping 
Because long-term enzymatic passaging method has been shown to cause karyotypic 
changes in hESCs, especially trisomy 12 and 17, the karyotype of hESCs passaged with 
the enzyme Tryple was determined. The karyotype analysis of hESCs grown with the 
Tryple culture method for 31 passages was performed by Laboratoriokeskus Ltd Tam-
pere, Finland.  
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 Approximately 25 individual cells at mitosis were analyzed by Giemsa-banding 
(G-banding) and further testing of the cells was done by fluorescence in situ hybridiza-
tion (FISH) analysis of chromosomes chosen based on the result of the G-banding. 
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5. Results 
5.1. The results of the test bFGF culture method for hESCs 
The human recombinant basic fibroblast growth factor (hrbFGF, from R & D Systems) 
used in hES-medium for hESCs used as control cells contains bovine serum albumine 
(BSA), and new hrbFGF from Chemicon without BSA was tested to replace it. The 
morphology of the hESC colonies in test bFGF culture method was thinner compared to 
control colonies with both cell lines (HS181 and HS237) used for testing (Figure 5), 
which made the test cells more difficult to passage mechanically.  
 
 
Figure 5. The morphology of the hESC colonies grown with the control culture method 
and with the test bFGF culture method. (A) HS181 control cells at passage 67, five days 
after splitting; (B) HS181 cells grown for 1 passage with 8 ng/ml of test bFGF, four 
days after passaging; (C) HS237 control cells at passage 63, six days after passaging; 
(D) HS237 cells grown for 3 passages with 8 ng/ml of test bFGF, five days after passag-
ing. Magnification 4x. Scale bar 500 µm. 
  
 The level of differentiation was judged by the morphologies of the colonies before 
they were passaged. With HS237 cells, the control bFGF promoted the growth of undif-
ferentiated cells better and there were fewer differentiated colonies compared to any 
concentration (8, 20 and 40 ng/ml) of the test bFGF (Figure 6). Similar results were 
obtained with HS181 cell line (data not shown). The test bFGF seemed to maintain 
undifferentiated hESC growth better as the concentration was raised, but it did not reach 
the control with the concentrations tested. 
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Figure 6. The level of differentiation of hESC colonies grown with the test bFGF cul-
ture method using 8, 20 and 40 ng/ml of test bFGF compared to the hESC colonies 
grown with the control culture method. n=198 for control group, n=53 for test bFGF 8 
ng/ml group, n=65 for test bFGF 20 ng/ml group and n=28 for test bFGF 40 ng/ml 
group. n=number of colonies. 
 
 The areas of the undifferentiated hESC colonies were measured daily and four 
different instant growth rates (G values) were calculated to each colony, between days 
2-3 (G1), 3-4 (G2), 4-5 (G3) and 5-6 after passaging (G4). The mean values of the test 
groups were compared to the mean value of the control group by one-way ANOVA for 
each time point (Figure 7). The differences between the groups were not statistically 
significant at p > 0,05, but the G values of hESC colonies grown with test bFGF culture 
method were the same or slightly higher than the G values of the control colonies al-
most every time. 
 The undifferentiated hESC colonies (judged by the morphology) grown with the 
test bFGF in all tested concentrations expressed markers common to undifferentiated 
hESCs (Nanog, Oct4, Alkaline phosphatase) and were negative to marker common to 
differentiated hESCs (SSEA-1) (Figure 8 and 9). 
 
 45
0,63
±0,29
0,53
±0,18
0,60
±0,22
0,69
±0,23
0,50
±0,15
0,50
±0,18
0,60
±0,18
0,54
±0,14 0,51
±0,11
0,56
±0,12 0,51
±0,12 0,47
±0,11
0,39
±0,08
0,39
±0,13
0,42
±0,07
0,38
±0,09
0,0
0,2
0,4
0,6
0,8
1,0
Co
nt
ro
l G
1
bF
GF
 8
ng
/m
l G
1
bF
GF
 2
0n
g/
m
l G
1
bF
GF
 4
0n
g/
m
l G
1
Co
nt
ro
l G
2
bF
GF
 8
ng
/m
l G
2
bF
GF
 2
0n
g/
m
l G
2
bF
GF
 4
0n
g/
m
l G
2
Co
nt
ro
l G
3
bF
GF
 8
ng
/m
l G
3
bF
GF
 2
0n
g/
m
l G
3
bF
GF
 4
0n
g/
m
l G
3
Co
nt
ro
l G
4
bF
GF
 8
ng
/m
l G
4
bF
GF
 2
0n
g/
m
l G
4
bF
GF
 4
0n
g/
m
l G
4
In
st
an
t 
g
ro
w
th
 r
at
e 
(m
ea
n
 ±
 S
D
)
 
Figure 7. The instant growth rates of undifferentiated hESC colonies grown with the 
test bFGF culture method compared to the colonies grown with the control culture 
method. The instant growth rates of the colonies in four different time points (between 
days 2-3, G1; days 3-4, G2; days 4-5, G3 and days 5-6 after passaging, G4) are pre-
sented as mean values.  
 
 Regardless of the similar instant growth rates of the hESC colonies grown with 
the test bFGF culture method and the culture method used for control cells, the test 
bFGF culture method did not expand the growth of hESCs equally well as the control 
culture method, because of the low percentage value of the undifferentiated colonies 
with the test bFGF culture method. When similar amount of pieces of hESC colonies 
are transferred to new plate in passaging, the undifferentiated hESCs from one culture 
plate grown with the test bFGF culture method could be passaged on to only one new 
culture plate, where as hESCs from one culture plate grown with the control culture 
method could usually be passaged on to three new culture plates, expanding the growth 
of hESCs (data not shown). 
 
 
Figure 8. The expression of Alkaline Phosphatase in the undifferentiated hESC colonies 
grown with the test bFGF culture method. (A) hESC colony grown for 5 passages with 
8 ng/ml of test bFGF; (B) hESC colony grown for 5 passages with 20 ng/ml of test 
bFGF; (C) hESC colony grown for 5 passages with 40 ng/ml of test bFGF. Magnifica-
tion 10x, scale bar 500 µm. 
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Figure 9. The expression of markers common to undifferentiated hESCs (Nanog and 
Oct4) and a marker common to differentiated hESCs (SSEA-1) in hESC colonies grown 
with the test bFGF culture method. (A) hESC colony grown for 5 passages with 8 ng/ml 
of test bFGF, five days after passaging, stained with DAPI and (B) showing the expres-
sion of Nanog(green) and SSEA-1(red), magnification 10x; (C) hESC colony grown for 
5 passages with 8 ng/ml of test bFGF, five days after passaging, stained with DAPI and 
(D) showing the expression of Oct4(green) and SSEA-1(red), magnification 10x; (E) 
hESC colony grown for 5 passages with 20 ng/ml of test bFGF, five days after passag-
ing, stained with DAPI and (F) showing the expression of Nanog(green) and SSEA-
1(red), magnification 10x; (G) hESC colony grown for 5 passages with 20 ng/ml of test 
bFGF, five days after passaging, stained with DAPI and (H) showing the expression of 
Oct4(green) and SSEA-1(red), magnification 20x; (I) hESC colony grown for 5 pas-
sages with 40 ng/ml of test bFGF, five days after passaging, stained with DAPI and (J) 
showing the expression of Nanog(green) and SSEA-1(red), magnification 10x; (K) 
hESC colony grown for 5 passages with 40 ng/ml of test bFGF, five days after passag-
ing, stained with DAPI and (L) showing the expression of Oct4(green) and SSEA-
1(red), magnification 20x. Scale bar 200 µm. 
5.2. The results of the SR-3 culture method for hESCs 
The serum replacement, SR-3 from Sigma-Aldrich, was tested on hESC culture by 
replacing the currently used SR (Gibco Invitrogen) that contains animal-derived com-
ponents. The presence of SR-3 in hESC culture medium did not promote the mainte-
nance of undifferentiated cells. The results were consistent in both hESC lines examined 
(HS237 and HS181). The data presented here is from HS237 cells. The number of 
undifferentiated colonies diminished significantly after second adaptation phase (1:1, 
SR-3:control SR) with both SR-3 concentrations tested (10 % and 20 %) and was lost 
completely when the control SR was left aside (Figure 10 and 11). The differentiation 
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was first judged by morphology and then confirmed by immunocytochemistry. The 
hESC colonies grown with the SR-3 culture method in both tested concentrations ex-
pressed a marker common to differentiated hESCs (SSEA-1) and were negative to a 
marker common to undifferentiated hESCs (Nanog) (Figure 13).  
5.3. The results of the X-Vivo 20 culture method for hESCs 
The tested animal-free X-Vivo 20 serum replacement medium did not maintain the 
growth of undifferentiated cells from hESC lines HS181 and HS237. The data presented 
here is from HS237 cells. The number of differentiated colonies grew as the amount of 
X-Vivo 20 medium was increased and the amount of hES-medium decreased. When 
there was no hES-medium present, all the colonies were differentiated (Figure 12). The 
differentiation was first judged by morphology and then confirmed by immunocyto-
chemistry. The hESC colonies grown with the X-Vivo 20 culture method expressed a 
marker common to differentiated hESCs (SSEA-1) and were negative to a marker 
common to undifferentiated hESCs (Nanog) (Figure 13). 
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Figure 10. The level of differentiation of hESC colonies grown with the SR-3 culture 
method in the adaptation phases and after the adaptation using 10 % SR-3. n=18 for 
adaptation phase 4:1 (Ko-SR:SR-3), n=33 for adaptation phase 1:1, n=62 for adapta-
tion phase 1:4 and n=12 after the adaptation. n=number of colonies. 
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Figure 11. The level of differentiation of hESC colonies grown with the SR-3 culture 
method in the adaptation phases and after the adaptation using 20 % SR-3. n=18 for 
adaptation phase 4:1 (Ko-SR:SR-3), n=15 for adaptation phase 1:1, n=37 for adapta-
tion phase 1:4 and n=7 after the adaptation. n=number of colonies. 
 
X-Vivo 20
0%
32%
60%
82%
0%
29%32%
18%
100%
39%
8%
0%
0
20
40
60
80
100
1:4 1:1 4:1 1
adaptation phase
undifferentiated partly differentiated differentiated
 
Figure 12. The level of differentiation of hESC colonies grown with the X-Vivo 20 
culture method in the adaptation phases and after the adaptation. n=17 for adaptation 
phase 4:1 (hES-medium:X-Vivo 20 medium), n=25 for adaptation phase 1:1, n=28 for 
adaptation phase 1:4 and n=9 after the adaptation. n=number of colonies. 
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Figure 13. The expression of a marker common to undifferentiated hESCs (Nanog) and 
a marker common to differentiated hESCs (SSEA-1) in hESC colonies grown with the 
SR-3 culture method with both tested concentrations of SR-3 (10 % and 20 %) and in 
hESC colonies grown with the X-Vivo 20 culture method. (A) hESC colony grown with 
the SR-3 culture method using 10 % SR-3, magnification 4x, (B) stained with DAPI and 
(C) showing the expression of Nanog (green) and SSEA-1 (red), magnification 10x; (D) 
hESC colony grown with the SR-3 culture method using 20 % SR-3, magnification 4x, 
(E) stained with DAPI and (F) showing the expression of Nanog (green) and SSEA-1 
(red), magnification 10x; (G) hESC colony grown with the X-Vivo 20 culture method, 
magnification 4x, (H) stained with DAPI and (I) showing the expression of Nanog 
(green) and SSEA-1 (red), magnification 10x. Scale bar 500 µm. 
5.4. The results of the Tryple culture method for hESCs 
The animal-free enzyme Tryple was preliminary tested for the passaging of hESCs by 
four different ways and one was chosen for the Tryple culture method (Figure 4 on page 
36). The other three techniques were (1) removing the feeders around the colonies 
without scalpel separation, (2) collecting all the cells in one clump and pipetting it into 
smaller pieces or (3) scalpelling it into smaller pieces. These other three techniques 
failed, mainly because of the tight cell-cell interactions of hESC colonies. If the colo-
nies were not lined with a scalpel, they detached with feeder cells and the effort to make 
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smaller pieces from one big cell clump by pipetting was not successful. The splitting 
could be done with a scalpel, but it was difficult and the resulted pieces were not small 
enough.  
The levels of differentiation of hESC colonies grown with the Tryple culture 
method were different from those grown with the control culture method. There were 
fewer partly differentiated colonies grown with the Tryple culture method than with the 
control culture method but the amount of undifferentiated colonies was higher (Figure 
14). The extended growth of hESCs grown with the Tryple culture method was more 
efficient than with the control culture method, because of the higher amount of undiffer-
entiated colonies with the Tryple culture method and because with the Tryple passaging 
method the hESC colonies could be passaged into even smaller pieces than the colonies 
grown with the control culture method (data not shown). This could be done because the 
pieces of hESC colonies were easier to detach from the plate after the Tryple treatment 
and it did not demand accurate needle handling.  
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Figure 14. The level of differentiation of hESC colonies grown with the Tryple culture 
method compared to the colonies grown with the control culture method. n=723 for the 
control group and n=1109 for the Tryple group. n=number of colonies. 
 
 The areas of the undifferentiated hESC colonies were measured daily and three 
different instant growth rates (G values) were calculated to each colony, between days 
2-3 (G1), 3-4 (G2) and 4-5 (G3) after passaging. The area of the colonies could not be 
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measured after day 5, because HS181 cells grow faster than HS237 cells and the colo-
nies did not fit into the picture taken by Nikon EclipseNet anymore. The mean values of 
the Tryple groups were compared to the mean values of the control group by one-way 
ANOVA for each time point (Figure 15). The differences between the groups were not 
statistically significant at p > 0,05.  
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Figure 15. The instant growth rates of undifferentiated hESC colonies grown with the 
Tryple culture method compared to the colonies grown with the control culture method. 
The instant growth rates of the colonies in three different time points (between days 2-3, 
G1; days 3-4, G2 and days 4-5 after passaging, G3) are presented as mean values. 
 
 The undifferentiated hESC colonies (judged by the morphology) grown with the 
Tryple culture method expressed markers common to undifferentiated hESCs (Nanog, 
Oct4, Alkaline phosphatase) and were negative to marker common to differentiated 
hESCs (SSEA-1) (Figure 16 and 17).  
The EBs were differentiated from hESCs to demonstrate the pluripotency of 
hESCs grown with the Tryple culture method. cDNA was made from the extracted 
RNA of the EBs and used in the RT-PCR analysis, which showed the differentiation of 
hESCs towards all the embryonic germ layers: ectoderm (ND-1 and NF-68), mesoderm 
(α-cardiac actin) and endoderm (AFP) (Figure 18). Although RT-PCR is only a semi 
quantitative method when similar amount of cDNA is used in the reactions, it could be 
said that these hESCs preferred to differentiate towards the ectoderm.   
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 The pluripotency of the cells was also confirmed at the protein expression level by 
immunofluorescense analysis of the sections of EBs using markers specific for the 
embryonic germ layers (ectoderm: sox-1 and Nestin, mesoderm: α-sarcomeric actin and 
endoderm: AFP) (Figure 19). 
 
 
Figure 16. The expression of Alkaline Phosphatase (common to undifferentiated 
hESCs) in hESC colony grown for 6 passages with the Tryple culture method, five days 
after passaging. Magnification 10x. Scale bar 500 µm. 
 
 
 Figure 17. The expression of markers common to undifferentiated hESCs (Nanog and 
Oct4) and a marker common to differentiated hESCs (SSEA-1) in hESC colonies grown 
with the Tryple culture method. (A) hESC colony grown for 5 passages with the Tryple 
culture method, six days after passaging, stained with DAPI and (B) showing the ex-
pression of Nanog (green) and SSEA-1 (red), magnification 10x; (C) hESC colony 
grown for 6 passages with the Tryple culture method, five days after passaging, stained 
with DAPI and (D) showing the expression of Oct4 (green) and SSEA-1 (red), magnifi-
cation 10x. Scale bar 500 µm.  
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Figure 18. RT-PCR analysis of embryoid bodies (EBs) differentiated from the hESCs 
grown with the Tryple culture method. EBs expressed genes specific for endodermal 
layer, α-fetoprotein (F, 216 bp); mesodermal layer, α-cardiac actin (C, 486 bp) and 
ectodermal layer, ND-1 (ND, 579 bp) and NF-68 (NF, 473 bp). GAPDH (G, 302 bp) 
was used as a housekeeping control and water control (-) as negative control for each 
primer pair. 
   
 
 
Figure 19. The immunofluorescense analysis of the sections of EBs differentiated from 
the hESCs grown for 16 passages with the Tryple culture method. (A) A section of EB 
stained with DAPI and (B) showing the expression of Sox-1 (ectodermal marker); (C) A 
section of EB stained with DAPI and (D) showing the expression of Nestin (ectodermal 
marker); (E) A section of EB stained with DAPI and (F) the showing the expression of 
α-sarcomeric actin (mesodermal marker); (G) A section of EB stained with DAPI and 
(H) showing the expression of AFP (endodermal marker). Magnification 10x. Scale bar 
500. 
 
  The karyotype of hESCs grown with the Tryple culture method for 31 passages 
was analyzed by Giemsa-banding (G-banding) method. At least 25 individual cells at 
mitosis were analyzed and 22 cells were found to have a normal 46,XX karyotype 
(Figure 20A). However, three of the cells had abnormal karyotypes, one having trisomy 
5, the other having trisomy 15, and the third having trisomy 16 and tetrasomy X (Figure 
20B). There were also few randomly missing chromosomes, for example missing chro-
mosome 11 from the cell that had also trisomy 16 and tetrasomy X. 
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Figure 20. The karyotype analysis of hESCs grown with the Tryple culture method for 
31 passages. (A) 22 cells out of 25 had normal karyotype 46,XX. (B) One cell out of 25 
had trisomy 16, tetrasomy X, and missing chromosome 11. 
 
 Because of the small amount of a missing or an extra chromosome in the cells and 
because there were no similar abnormalities between the cells, these aneuploidies could 
be considered as artifacts caused by the method. The harsh spreading of the chromo-
somes at mitosis into the slides might have caused a misplacement of the chromosomes 
from the mitosis of one cell to the mitosis of another, resulting in missing or extra 
chromosomes in some cells. However, the tetrasomy X had to be further analyzed by 
fluorescence in situ hybridization (FISH) method. 1142 cells were analyzed by FISH 
with the X chromosome centromere probes and only three cells were found to have 
three X chromosomes (0.6 %) and only two cells had four X chromosomes (0.4 %) 
whereas the rest had the normal two X chromosomes (99 %) (Figure 21). Further con-
firmation was done for the hESCs grown with the Tryple culture method for 35 pas-
sages, using the X chromosome centromere probe and the chromosome 16 centromere 
probe as a control. The further analysis of 200 individual cells did not reveal any addi-
tional abnormalities.  
 There might occasionally be false missing signals or false positive signals when 
FISH method is used. The found extra X chromosomes might have been artifacts caused 
by the FISH method. Although the abnormal karyotypes found for some of the cells 
might have been real and not artifacts, it could be stated that hESCs grown with the 
Tryple culture method have normal 46,XX karyotype, because of the low percentage of 
the abnormal karyotypes. If the found mutations were real they were not clonal and did 
not give a growth advantage to the cells.   
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Figure 21. The FISH analysis of hESCs grown with the Tryple culture method. (A) 200 
cells out of 200 grown with the Tryple culture method for 35 passages had two X chro-
mosomes and two chromosomes 16; (B) 2 cells out of 1142 grown with the Tryple 
culture method for 31 passages had four X chromosomes.   
5.5. The results of the biomaterial culture method for hESCs 
Three different biomaterials (TiO2, Ti and Zr coated glass pieces from Vivoxid Ltd) 
were tested for the feeder-free culture of hESCs. Two different media were used in the 
testing, unconditioned medium (UM) and conditioned medium (CM) from human 
foreskin fibroblasts (hFFs). The hESCs used in the testing did not attach to any of the 
biomaterials in the presence of UM, but attached to all biomaterials when CM was used. 
The hESCs did not attach to the chamber glass used as control.  
 The hESCs grew on the biomaterials in CM for 4 days, after which they started to 
detach. The morphology of the colonies grown on the biomaterials was different from 
the morphology of the colonies grown on feeder cells (Figure 22), therefore the level of 
differentiation could not be judged according to the morphology. The morphologies of 
the colonies grown on the three different biomaterials were similar. 
 
 
Figure 22. The morphology of the hESC colonies grown on the tested biomaterials. (A) 
hESC colony grown on TiO2 coated glass for 4 after passaging, magnification 4x, scale 
bar 500 µm; (B) hESC colony grown on Ti coated glass for 4 days after passaging, 
magnification 4x, scale bar 500 µm; (C) hESC colony grown on Zr coated glass for 2 
days after passaging, magnification 10x, scale bar 100 µm.  
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 The hESCs grown on the biomaterials could not be passaged by conventional 
methods because they detached easily as single cells and did not attach to the biomate-
rials anymore. The immunocytochemistry analysis of the hESC colonies on the bioma-
terials was not successful due to the difficulties in the fixation of the cells as well as in 
the staining of false positives. The level of differentiation of hESCs grown on the bio-
materials was judged after the cells colonies were transferred back on the feeder cells 
and allowed to proliferate. The morphology of the resulted colonies was similar to 
undifferentiated colonies grown on feeder cells. Although the hESC colonies expressed 
a marker common to undifferentiated hESCs (Nanog), they also expressed a marker 
common to differentiated hESCs (SSEA-1) (Figure 23). The results were consistent 
with all the tested biomaterials (the data from hESCs grown on TiO2 and Zr coated glass 
is not shown). 
 
 
Figure 23. The morphology of the hESC colonies grown on feeder cells after one pas-
sage on Ti coated glass and the expression of a marker common to undifferentiated 
hESCs (Nanog) and to differentiated hESCs (SSEA-1). (A) hESC colony grown for five 
days after passaging, magnification 4x, (B) stained with DAPI and (C) showing the 
expression of Nanog (green) and SSEA-1 (red), magnification 10x. Scale bar 500 µm. 
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6. Discussion 
6.1. The test bFGF culture method for hESCs 
The human recombinant basic fibroblast growth factor (hrbFGF) from Chemicon was 
selected to the study because it was the only totally animal-free bFGF in the markets in 
the beginning of this project. The bFGF (from R & D Systems), used as control in this 
study, was also human recombinant protein but contained small amounts of bovine 
serum albumine (BSA) and is therefore not suitable for the culture of clinical grade 
hESCs.  
 Although undifferentiated hESCs were reached with the test bFGF culture 
method, proven by immunocytochemistry, the test bFGF did not maintain the undiffer-
entiated growth equally well as the control bFGF. The test bFGF did not promote the 
expanded growth of hESCs equally well, because the amount of the undifferentiated 
colonies with all the tested concentrations of test bFGF was significantly smaller than 
with the control bFGF. However, the test bFGF maintained the undifferentiated growth 
of hESCs better as the concentration was raised. This may result from the possible rapid 
degradation of the growth factor in the culture medium; the higher the starting concen-
tration the higher the finishing concentration before medium exchange. Levenstein et al. 
have stated that bFGF is degraded faster in an unconditioned medium (UM) than in a 
medium conditioned in fibroblast culture, indicating that fibroblasts may excrete some 
molecules to the medium that stabilizes bFGF (Levenstein et al., 2006). But in this 
study, human foreskin fibroblasts  (hFFs) were used in both the control bFGF culture 
method and the test bFGF culture method suggesting that the possible FGF stabilizer 
factor should be present in both culture conditions. However, the added BSA in the 
control bFGF may have resulted in the differences in the maintenance of undifferenti-
ated growth of hESCs between the control and the test bFGF. It is well known that BSA 
prevents adhesion of proteins to reaction tubes and stabilizes enzymes during incubation 
steps. It may also protect purified recombinant proteins from proteolytic degradation by 
contaminating proteases. Even though the culture medium containing the test bFGF 
(without BSA) was aliquoted and preserved in +4 °C maximum of one week, and the 
culture medium for hESCs was changed daily, the degradation of the bFGF might have 
been too fast. After 24 hours in the +37 °C the amount of bFGF left may have been 
inadequate to maintain the hESCs undifferentiated. Another possibility is that bFGF had 
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attached to the tube containing the medium and no or only a small amount of bFGF had 
been transferred to the cell culture. BSA seems to play a major role in the function of 
bFGF, but maybe human serum albumine (HSA) could be used instead. HSA could be 
added to bFGF stocks before freezing, ensuring its preservation after thawing. 
 The instant growth rates of the undifferentiated colonies grown with the test bFGF 
culture method were similar to the instant growth rates of the colonies grown with the 
control bFGF. Although there were no statistically significant differences between the 
instant growth rates, the undifferentiated colonies grown with the tested bFGF had the 
same or slightly higher instant growth rates than the colonies grown with the control 
bFGF. This may be caused by the error in the area measurement of the colonies that 
does not account the upright growth of the cells. Because the morphology of the hESC 
colonies grown with the test bFGF was thinner than the morphology of the colonies 
grown with the control bFGF the instant growth rates of the colonies grown with the test 
bFGF are probably much lower. 
 It is reported that the presence or absence of exogenous bFGF does not signifi-
cantly affect the proliferation rate of hESCs (Dvorak et al., 2005), which could explain 
that there were no statistically significant difference between the instant growth rates of 
the colonies grown with the test bFGF and the control bFGF. But this does not explain 
the morphology differences between the colonies grown with the test bFGF and with the 
control bFGF. The morphology differences could result only from the differences 
between the growth factors, because two different cell lines were tested and they both 
gave the same result and exactly the same culturing conditions were used for the hESCs 
cultured with the control bFGF and with the test bFGF. Besides the absence or presence 
of BSA, the growth factors had another difference; their amino acid sequences differ 
slightly. The control bFGF consists of 157 amino acid residues and its molecular mass 
is 17,4 kDa (Florkiewicz and Sommer, 1989), whereas the test bFGF consists of 154 
amino acids and is 17,2 kDa. The difference is only three amino acids, but it could have 
a major effect on the proper folding of the protein. The amino acid sequence of the test 
bFGF is not provided by the manufacturer, so no protein structure comparison could be 
made. The missing amino acids could be critical for example for the proper folding of 
the binding site of bFGF that is needed to attach to the receptor and to activate the 
response pathway. The missing amino acids could have effect also on the folding of the 
active site of the growth factor, changing the ability of bFGF to produce the needed 
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signal for the activation of the pathway. The difference could also expose hydrophobic 
amino acids elsewhere in the protein, making it more vulnerable to proteolysis.         
 According to the results of this study, hrbFGF from Chemicon is not suitable for 
hESC culture. The result was unexpected because of the small differences between the 
two growth factors. This bFGF should be tested again by adding HSA to the protein 
stock. However, a recent report from Xiao et al. revealed that exogenously added bFGF 
could be replaced by Activin A (Xiao et al., 2006). The medium containing Activin A 
maintained the hESCs in an undifferentiated state on Matrigel coating without either 
feeder cells or conditioned medium (CM). It was discovered that Activin A maintains 
the expression of Oct4 and Nanog ten times higher than bFGF and at lower concentra-
tions also. Only 5 ng/ml of Activin A was sufficient compared to 100 ng/ml of bFGF in 
the culture of hESCs grown also on Matrigel and UM (Li et al., 2005). The use of 
Activin A should be tested also in the feeder cell culture of hESCs.    
6.2. The SR-3 and X-Vivo 20 culture methods for hESCs 
Because the currently used serum replacement (SR) from Gibco Invitrogen contains 
animal-derived products, several different animal-free SR were tested in our laboratory. 
SR-3 from Sigma-Aldrich as well as ready-made SR medium, X-Vivo 20, from Cam-
brex were included into this study. Li et al. reported the expansion of hESCs on Ma-
trigel using unconditioned X-Vivo 10 medium from Cambrex (Li et al., 2005). X-Vivo 
10 was tested in our laboratory and X-Vivo 20 were chosen to the tests also, although 
using hFFs as feeder cells.  
  Neither SR-3 nor X-Vivo 20 were able to maintain hESCs undifferentiated. After 
the third adaptation phase (1:4, control:test SR) there started to be more differentiated 
than undifferentiated colonies in the culture. The differentiation stage was judged by the 
morphology of the colonies and they were divided into three classes; undifferentiated, 
partly differentiated and differentiated. The evaluation of the differentiation stage is not 
very accurate, but the result in the last adaptation phase is clear, 100 % of the colonies 
were completely differentiated. The tested SR and SR-medium may require higher 
concentrations of bFGF to maintain the undifferentiated growth of hESCs. Li et al. used 
80 ng/ml of bFGF instead of the 8 ng/ml used in this study (Li et al., 2005). However, 
the high concentration used in their study might be required because of the feeder-free 
culture without fibroblasts.  
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 After the adaptation of both SR-3 and X-Vivo 20, the fibroblasts started to detach 
from the borders of the plate (data not shown). Because feeder cells are an important 
part of this culture system, this might have a big effect on the differentiation of the 
hESCs. It is reported that ascorbic acid deficiency in fibroblast culture causes, among 
other things, an easy disaggregation of the cells from the intracellular matrix by protease 
(Schafer et al., 1967). The control SR (Ko-SR from Gibco Invitrogen) contains ascorbic 
acid, but it is not know what the tested SR-3 and X-Vivo 20 contain. They might lack 
ascorbic acid and the tests should be done again using additional ascorbic acid in the 
culture medium. The missing or presence of other components in the tested SRs may 
also have influenced the differentiation of hESCs. It is certain that the ingredients of the 
control and the test SR and SR medium differ, because once the control SR is entirely 
replaced, the differentiation of the hESCs is complete. The ingredients should be de-
tected and compared so that the differences could be seen. Ludwig et al. reported re-
cently the use of a new animal-free culture medium for hESCs, TeSR1 (Ludwig et al., 
2006). They developed the medium based on the ingredients used in the Ko-SR from 
Gibco Invitrogen, replacing the animal-derived products with human material or recom-
binant proteins. In addition, they used a combination of collagen IV, fibronectin, 
laminin and vitronectin coating from human sources instead of feeders or Matrigel. 
Ludwig et al. managed to derive two hESC lines in these animal-free conditions, al-
though only the other maintained stable karyotype. This report is a great step forward in 
hESC culture, but a great deal of improvement must still be made. The TeSR1 medium 
contains various ingredients, of which many are used in high concentrations making the 
medium very expensive. Ludwig et al. tested the effect of the absence of several ingre-
dients, and resulted that all of them are needed in the medium, but the results shown in 
the article are not clear with every ingredient and some of them might be unnecessary 
for the maintenance of undifferentiated hESCs. Also the purified human matrix compo-
nents used in the coating are expensive and the data from which the combination was 
chosen is not shown. Although they found no expression of nonhuman sialic acid, 
Neu5Gc, in cultured hESCs, the human matrix components provide a potential route of 
contamination by human pathogens. In addition Ludwig et al. used only two different 
hESC lines and they continued the testing for the cells only three passages. Because of 
the differences between the hESC lines, the culture method should be tested with sev-
eral hESC lines and in three passages, the hESCs might not have been adapted to the 
new medium properly, making these results incomplete.   
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6.3. The Tryple culture method for hESCs  
Tryple Select from Gibco Invitrogen is an animal-free enzyme, which is designed to 
replace trypsin in the passaging of cells. The possibilities of Tryple for hESC passaging 
were tested in different ways. Oh et al. used an interesting passaging method with 
collagenase IV (Oh et al., 2005). The collagenase incubation resulted in the pealing off 
of the colonies, which were collected into a test tube. The colonies were allowed to 
settle on the bottom of the tube and the resulting supernatant, containing feeder cells 
and single cells could be discarded. The remaining colonies were pipetted to smaller 
pieces and then plated. The same method was tested with Tryple, but the colonies did 
not peal of. However, Tryple detached all the cells from the plate very efficiently (in 1 
minute), but even an hour of incubation did not affect the cell-cell interactions. 
 The hESCs and the feeder cells were collected into a clump, which was tried to 
pipette into a smaller pieces. The splicing of the clump could be done only with a scal-
pel, but that resulted in too large pieces. The feeder cells were tried to pull out as one 
“carpet” at the same time leaving the hESC colonies intact, assuming that the colonies 
would still be attached to the plate. However, all the colonies detached with the feeder 
cells. The only way to leave the colonies in the plate and remove the feeders, was to line 
the colonies with a scalpel before removing the feeders.  
 The SR used in the hESCs medium may cause the tight cell-cell interactions and 
make the passaging of the cells difficult. If fibroblasts are cultured in medium contain-
ing SR the passaging with trypsin is almost impossible, because the fibroblasts form a 
similar “carpet” as in the Tryple-testing (unpublished data). Oh et al. did not report the 
medium they used, so it is possible that their passaging method is possible only in a 
serum containing culture (Oh et al., 2005). 
 The Tryple passaging method was as laborious as the original mechanical passag-
ing and the same skills were required for both methods. However, it was easier to 
detach the scalpeld pieces from the plate after Tryple treatment. In mechanical passag-
ing, the pieces are sometimes hard to detach with a needle, which results in torn pieces 
that do not easily attach to new feeder plates. It was also easier to detach smaller pieces 
after Tryple treatment than with original mechanical passaging, which can result in 
more expanded growth of hESCs.  
 The Tryple culture method maintained the undifferentiated growth of hESCs, 
proven by immunocytochemistry analysis, and the amount of undifferentiated and partly 
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differentiated colonies was similar with the control culture method, allowing the ex-
panded growth of the hESCs similarly as the control method. The instant growth rates 
between the hESC colonies grown with the control culture method and with the Tryple 
culture method did not have statistically significant differences. The hESCs cultured 
with Tryple method remained pluripotent, which is shown from the differentiation of 
the embryoid bodies into all three embryonic germ layers. The results of the RT-PCR 
analysis indicates that the hESCs grown with the Tryple culture method preferred to 
differentiate towards the cells representing the ectoderm layer. These cells could be 
more easily differentiated for example to neurons.            
 The enzymatic passaging method may cause karyotypic chances in hESCs, espe-
cially trisomy 12 and/or 17 (Draper et al., 2004b; Mitalipova et al., 2005). The muta-
tions may result from the harsh enzyme treatment that affects all the cells in the culture 
plate, whereas mechanical passaging stresses only the cells that are in the borders of the 
passaged piece of a cell colony. On the other hand, the mutations may result from the 
passaging method and not from the enzyme itself. There are often a lot of single cells 
after the enzymatic passaging of the cells and it is known that hESCs prefer the cell-cell 
contacts. Proliferation from a single cell may cause pressure to the cell and it might 
need chromosomal mutations to survive. Although the Tryple culture method did not 
allow the cells to detach as single cells, an enzyme was used for the passaging and 
therefore the analyzing of the karyotype of these cells was important. 
 The karyotype analysis of hESCs grown with the Tryple culture method was 
performed by Giemsa-banding (G-banding) and fluorescence in situ hybridization 
(FISH) method by Laboratoriokeskus Ltd, where these methods for hESCs are currently 
optimized. Twenty-two cells out of 25 were found to have normal 46,XX karyotype by 
G-banding method whereas three of these cells had abnormal karyotypes. These found 
abnormalities were all different from each other and none of them were the most com-
monly occurred mutations found from the hESCs (neither trisomy 12 nor trisomy 17). 
One of these found mutations was tetrasomy X, where two extra X chromosomes were 
present in the cell. This possible mutation was further analyzed by FISH from the cells 
grown with the Tryple culture method for 31 passages, which revealed only three cells 
with one extra X chromosome and only two cells with two extra X chromosomes out of 
1142 cells examined. In this experiment, only the centromere probes for X chromo-
somes were used and no other probes for different chromosome as a control were used. 
This caused uncertainty in the interpretation of the results, because it could not be 
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determined that were there only extra X chromosomes or was the entire genome of the 
cell triploid or tetraploid. The hESCs grown with the Tryple culture method for 35 
passages were further analyzed by FISH using X chromosome centromere probe and the 
chromosome 16 centromere probe as a control. These additional 200 individual cells 
were examined and no abnormalities were found. 
 The percentage of the abnormal karyotypes found is so low that they might be 
artifacts caused by the methods used. The G-banding and FISH method for hESCs were 
not yet fully optimized in Laboratoriokeskus Ltd at the time of this study and the occur-
rence of artifacts was quite probable. Although the found abnormalities would have 
been real and not artifacts, the mutations were not clonal and did not gave the cells any 
growth advantage, because no similarly mutated cells were found with G-banding. 
These mutations would probably be left off from the later passages. It can be stated that 
the hESCs grown with the Tryple culture method have normal 46,XX karyotype even 
after 31 passages. The common karyotypic changes caused by the enzymatic passaging 
methods usually occur after extended culture of hESCs. Mitalipova et al. found karyo-
typic changes after 23 passages when cell dissociation buffer was used and after 25 
passages after collagenase or trypsin were used for passaging (Mitalipova et al., 2005). 
The results of this study indicate that Tryple culture method might maintain stable 
karyotype better than the methods were trypsin, collagenase or cell dissociation buffer is 
used. These results might also reinforce the theory that karyotypic mutations occur if 
the cells are passaged as single cells and that the enzyme itself does not cause the muta-
tions. 
 The karyotype of the cells grown with the Tryple culture method must be ana-
lyzed regularly to make sure that no changes will occur later and that the possible 
mutations found now are not multiplied in the later passages. The karyotype of the 
HS181 cells used as control cells must also be analyzed so that the effect of Tryple 
culture method can be shown and the effect of the age of the cell line can be left out. In 
conclusion, the Tryple culture method can be recommended for the expansion of hESCs 
and it is a good choice for passaging hESCs, especially cell lines with thin morpholo-
gies.  
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6.4. The biomaterial culture method for hESCs 
Three different biomaterials were tested in cooperation with Vivoxid Ltd from Turku. 
Because titania coatings in implants results in good soft tissue attachment (Areva et al., 
2004), the coating was decided to test for hESC attachment. Besides titania (TiO2) 
testing, also titanium (Ti) and zirconium (Zr) coatings were tested because they have 
similar properties with titania. 10 mm x 10 mm glass pieces were coated in a manner 
described in Areva et al. 2004, and placed on a culture chamber. Human ESCs did not 
attach to the biomaterials in the presence of normal hES-medium (unconditioned me-
dium), but cells attached to all the biomaterials in conditioned hES-medium similarly as 
reported with other feeder-free methods such as Matrigel (Xu et al., 2001). Feeder cells 
must secrete some molecules that assist this attachment. The pieces of the hESC colo-
nies did not attach to culture chamber glass used as control, indicating that the coatings 
have also some effect on the attachment. The percentage values of the attachment was 
not able to record because the testing was difficult, mainly because the small size of the 
biomaterials. The culture chamber was twice as big as the biomaterial and only a small 
bump was needed to dislocate the cell clumps from the biomaterials before the attach-
ment. 
   The cell clumps that attached proliferated for four days, after which the cells 
started to detach. The morphology of the colonies was totally different from those 
grown on feeder cells, but because the feeder layer influences the shape of the colonies 
a lot, no conclusions about the differentiation stage could be made. The morphology of 
the colonies grown on the biomaterials resembles that grown on fibronectin matrix 
(Amit et al., 2004), but they were less compact. The cells were tried to analyze with 
immunocytochemistry, but the fixation of the cells was difficult and when the fixation 
worked the immunostaining gave false positive results. New methods for fixation and 
for immunostaining of these cells should be developed and optimized. 
 The passaging of the cells grown on the biomaterials was impossible with the 
techniques in hand. The cells detached easily as single cells and they did not attach to 
the biomaterials after that. A new passaging method should be created in order to test 
the ability of the biomaterials to maintain the growth of the cells. The analysis of the 
differentiation stage of the hESCs grown on the biomaterials was done by transferring 
the cells back on feeder cells. The colonies grown on the biomaterials for one passage, 
were detached in as big piece as possible and the pieces were then transferred back on 
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feeders and allowed to proliferate for five days. The morphology of the resulting colo-
nies was similar to undifferentiated colonies grown on feeder cells, but the immunocy-
tochemistry analysis of the colonies showed the expression of SSEA-1 indicating the 
presence of differentiated hESCs. There were also some cells positive to Nanog (ex-
pressed in undifferentiated hESCs), but because the cells were maintained only one 
passage on the biomaterials, the undifferentiated cells may have preserved on the bio-
materials in the piece, which was transferred to the biomaterials.  
 No finite conclusions can be made from the convenience of these biomaterials to 
the culture of hESCs. New methods should be optimized and a large scale testing would 
be needed. The size of the biomaterial should be bigger and the best choice would be a 
culture plate coated with these materials. No differences between the three materials 
were observed in this small scale testing and further testing is required.     
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7. Conclusions 
One of the aims of this study, and perhaps the most important one, was to optimize 
culturing conditions for human embryonic stem cells (hESCs) towards animal-free 
conditions. Human recombinant basic fibroblast growth factor (hrbFGF) from Chemi-
con, serum replacement SR-3 from Sigma-Aldrich and serum replacement medium X-
Vivo 20 from Cambrex were tested for this purpose. All of these tested components 
failed to maintain the growth of undifferentiated hESCs better than the control condi-
tions. Although this aim was not reached in this study, a lot of valuable information was 
gained and a direction of new testing was accomplished.  
 Development of an easier way for hESC passaging was the second aim of the 
study. No universally easier way was found, but based on the results and the experience 
from the Tryple culture method, it is useful in passaging hESC colonies with thin mor-
phologies and it could be used to result in faster expanded growth of hESCs than the 
conventional mechanical passaging. In addition, the hESCs grown with the Tryple 
culture method for 31 passages had normal 46,XX karyotype making Tryple enzyme a 
better option for the currently used enzymes.    
  The tested biomaterials could not yet be used to maintain the undifferentiated 
growth of hESCs instead of feeder cells. Although this aim also remains to be reach, the 
study raised several questions about biomaterials and their potential. Biomaterials could 
be the perfect choice for feeder cells, but before it can be proofed, the factors maintain-
ing the undifferentiated growth of hESCs must be better determined.  
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